Published by the Australian Commission on Safety and Quality in Health Care  
Level 5, 255 Elizabeth Street, Sydney NSW 2000

Phone: (02) 9126 3600  
Fax: (02) 9126 3613

Email: mail@safetyandquality.gov.au   
Website: www.safetyandquality.gov.au

ISSN (print): 2200-3126  
ISSN (online): 2200-7777

© Australian Commission on Safety and Quality in Health Care 2017

All material and work produced by the Australian Commission on Safety and Quality in Health Care is protected by copyright. The Commission reserves the right to set out the terms and conditions for the use of such material.

As far as practicable, material for which the copyright is owned by a third party will be clearly labelled. The Australian Commission on Safety and Quality in Health Care has made all reasonable efforts to ensure that this material has been reproduced in this publication with the full consent of the copyright owners.

With the exception of any material protected by a trademark, any content provided by third parties, and where otherwise noted, all material presented in this publication is licensed under a **Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence**.



Enquiries regarding the licence and any use of this publication are welcome and can be sent to communications@safetyandquality.gov.au.

The Commission’s preference is that you attribute this publication (and any material sourced from it) using the following citation:

Australian Commission on Safety and Quality in Health Care. Annual Report 2016–17. Sydney: ACSQHC; 2017

**Disclaimer**

The content of this document is published in good faith by the Australian Commission on Safety and Quality in Health Care for information purposes. The document is not intended to provide guidance on particular healthcare choices. You should contact your healthcare provider on particular healthcare choices.

The Commission does not accept any legal liability for any injury, loss or damage incurred by the use of, or reliance on, this document.

# Letter of transmittal

|  |
| --- |
| Logo  **The Honourable Greg Hunt MP  Minister for Health** Parliament House  Canberra ACT 2600  Dear Minister  On behalf of the Board of the Australian Commission on Safety and Quality in Health Care (the Commission), I am pleased to submit our Annual Report for the financial year ending 30 June  2017.  This report was prepared in accordance with the requirements of the National Health Reform Act 2011 and section 46 of the Public Governance, Performance and Accountability Act 2013.  The report includes the Commission’s audited financial statements, as required by section 42 of the Public Governance, Performance and Accountability Act.  The Commission’s annual performance statements were prepared in accordance with the requirements of section 39 of the Public Governance, Performance Accountability Act and accurately present the Commission’s performance from 1 July 2016 to 30 June 2017.  As required by section 10 of the Public Governance, Performance and Accountability Rule 2014, I certify on behalf of the Board that:   * The Commission has prepared fraud risk assessments and fraud control plans * The Commission has in place appropriate fraud control mechanisms that meet its specific needs * All reasonable measures have been taken to deal appropriately with fraud relating to the Commission.   This report was approved for presentation to you in accordance with a resolution of the Board on 13 September 2017.  I commend this report to you as a record of our achievements and compliance.  Yours sincerely    **Professor Villis Marshall AC** Chair  Australian Commission on Safety and Quality in Health Care 13 September 2017 |

1. Overview 5

About the Commission 6

Report from the Chair 8

Report from the CEO 10

Strategic Plan 2016–2019 12

1. Report on performance 15

Priority 1: Patient safety 16

Priority 2: Partnering with patients, consumers and communities 33

Priority 3: Quality, cost and value 37

Priority 4: Supporting health professionals to provide safe and high-quality care 44

The state of safety and quality in Australian health care 47

Annual performance statements 49

1. Corporate governance and accountability 59

Legislation and requirements 60

Compliance with legislation 60

Strategic planning 60

Ministerial directions 60

Commission Board 61

Committees 67

Internal governance arrangements 69

External scrutiny 70

Developments and significant events 71

Environmental performance and   
ecologically sustainable development 71

Advertising and market research 71

National Health Reform Act amendments 71

Government policy orders 71

1. Our organisation 73

Organisational structure 74

People management 76

Staff profile 76

Workplace health and safety 77

Learning and development 77

Disability strategy 78

Indigenous employment 78

1. Financial statements 81

Independent auditor’s report 82

Financial Statements 84

Notes to and forming part of the financial statements 89

1. Appendices 107

Appendix A: Freedom of   
information summary 108

Appendix B: Compliance with   
ecologically sustainable development 109

Appendix C: Related-entity transactions110

1. Indexes and references 113

Acronyms and abbreviations 114

Glossary 116

Index of tables 119

Index of figures 119

Compliance index 120

Index 123

References 128

Overview

This section provides an overview of the Australian Commission on Safety and Quality in Health Care (the Commission) – including its mission, role, functions and accountability – and reports from the Commission’s Chair and Chief Executive Officer (CEO).

|  |  |
| --- | --- |
| About the Commission | 6 |
| Report from the Chair | 8 |
| Report from the CEO | 10 |
| Strategic Plan 2016–2019 | 12 |

# About the Commission

|  |
| --- |
| In 2006, the Council of Australian Governments (COAG) established the Commission to lead and coordinate national improvements in the safety and quality of health care. The Commission’s permanent status was confirmed with the passage of the National Health and Hospitals Network Act 2011, while its role was codified in the National Health Reform Act 2011. The Commission commenced as an independent statutory authority on 1 July 2011, funded jointly by the Australian Government and state and territory governments. |

## Our mission

The Commission’s mission is to lead and coordinate national improvements in the safety and quality of health care.

## Our role and functions

The Commission provides health ministers with strategic advice on best practices to improve healthcare safety and quality, and makes recommendations about priority areas for action. The Commission also develops national initiatives to better inform, support and organise the delivery of safe and high-quality health care in Australia, contributing to improved health outcomes for patients, consumers and communities.

|  |
| --- |
| The Commission works in four priority areas:  **1.** Patient safety  **2.** Partnering with patients, consumers and communities  **3.** Quality, cost and value  **4.** Supporting health professionals to provide safe and high-quality care. |

The National Health Reform Act specifies the Commission’s roles and responsibilities as a corporate Commonwealth entity under the Public Governance, Performance and Accountability Act 2013.

## Our accountability

The Commission is a corporate Commonwealth entity and part of the Health portfolio of the Australian Government.   
As such, it is accountable to the Australian Parliament and the Minister for Health,   
the Honourable Greg Hunt.

Report from the Chair

Professor Villis Marshall AC

Millions of patient encounters take place across Australia’s health system each year. Generally, patients receive an excellent standard of care during these interactions. Treatments and technologies have improved to the point where we have much better health outcomes than previous generations.

However, excellence in health care is relative, and is more akin to a process than a condition. Each success cannot be an end in itself, but rather a stepping stone to the next achievement. This is particularly apposite for the Commission’s work. Better medicines and surgical techniques explain some of the health gains of recent decades, but better checks and balances, better systems, better partnerships and better ways of working are also fundamental.

In 2016–17, the Commission made a further significant contribution to these advances, covering safety perspectives, quality and appropriateness of care, support for practitioners and better resources for patients and consumers.

The Commission’s foundational piece of work is the National Safety and Quality Health Service (NSQHS) Standards, which were introduced in 2011. The NSQHS Standards have had a very positive effect on the Australian health system and are responsible for a number of tangible and significant improvements nationally and at the local level. The Commission has built on this success by incorporating the lessons learnt from the NSQHS Standards into the development of the second edition of the NSQHS Standards, which have been approved by Australian health ministers. The second edition of the NSQHS Standards is due to be launched later this year and will consolidate and extend the positive impacts already seen.

Similarly, the launch of the Australian Atlas of Healthcare Variation in November 2015 proved a catalyst for focusing on appropriateness of care. Recommendations in the first Atlas prompted the Commission to start work on a number of new clinical care standards – including one on osteoarthritis of the knee, which was launched in May 2017. These recommendations helped shape the design of the Second Australian Atlas of Healthcare Variation, launched in June, so that key issues could be explored in greater detail.

Likewise, the Commission has built on its previous work in supporting healthcare professionals, and also consumers, with a range of new products, documents and other resources. These include a suite of documents designed to help clinicians identify and prevent hospital-acquired complications, as well as many other valuable tools in the areas of antimicrobial resistance, medication safety and e-health, cognitive impairment and mental health care. The Commission is also seeking to engage consumers more than ever before: this year the Commission has released decision-support aids for consumers, a revised list of healthcare ‘top tips’, and an innovative online ‘question builder’ designed to help members of the public navigate their healthcare journey more confidently.Each of these examples shows the Commission becoming more sophisticated in delivering on its mission to lead national improvements in the safety and quality of health care. The huge improvements already seen in health care mean that the nature of the improvement challenge is changing: new and more complex approaches must be developed to ensure further improvements can be made. The Commission is ready for this challenge, and I look forward to its progress and its success in the coming year.

My thanks go to the members of the Commission’s Board for their advice throughout 2016–17. On behalf of Board members, I would also like to thank Minister Hunt, the Commission’s executive team and employees for their continued commitment to delivering our work priorities. Their significant achievements are described in detail throughout this report.

Report from the CEO

Adjunct Professor Debora Picone AM

This has been a year of outstanding achievement for the Commission and its partners. This annual report is a snapshot of the Commission’s work in collaboration with the Australian Government and state and territory governments, clinicians, consumer and patient groups, and the private sector in improving the safety and quality of the Australian healthcare system.

I am pleased to report that the implementation of the National Safety and Quality Health Service (NSQHS) Standards continues to be a success, with 100% of health services assessed against the NSQHS Standards at least once, and a number having undergone a second assessment.

After extensive consultation, the second edition of the NSQHS Standards has been completed and approved by the COAG Health Council. The Commission has also undertaken significant consultation on supporting documentation including an NSQHS Standards user guide for Aboriginal and Torres Strait Islander services, resources for hospitals, multipurpose services and day procedure services, and fact sheets for consumer organisations. The Commission continues to provide implementation support and advice via the NSQHS Standards Advice Centre.In June, the Commission launched the   
*Second* Australian Atlas of Healthcare Variation. As with the first Atlas, the second Atlas demonstrates significant variations in treatment for the same conditions across Australia. The second Atlas has a focus on acute care, with indicators in the areas of surgical interventions, women’s and maternity health, chronic disease and infection, and cardiovascular conditions. One of the innovations in the second Atlas is being able to look at data in new ways, including whether treatment was publicly or privately funded,   
and according to Aboriginal and Torres Strait Islander status.

The Atlas project is a key part of the Commission’s priority to support the health system to reduce unwarranted clinical variation. This year we have released three clinical care standards – on hip fracture care, delirium, and most recently on appropriate treatment for osteoarthritis of the knee, one of the indicators featured in the first Atlas. We will be releasing more clinical care standards in the coming year, including one relating to treatment for heavy menstrual bleeding arising from data in both atlases on variation in rates of endometrial ablation and hysterectomy.

The Commission is the lead agency responsible for coordinating Australia’s response to antimicrobial resistance, and our national Antimicrobial Use and Resistance in Australia (AURA) surveillance program continues to grow. There are now 159 hospitals across Australia participating in antibiotic usage monitoring and 281 are contributing information on appropriateness.

Supporting consumers to be partners in their own health care is critical to improving safety and quality. This year we have released a revised and updated version of one of our important resources for consumers and primary care practitioners, *Top Tips for Safe Health Care*. We also released the Question Builder, a web-based tool designed to help patients ask the questions that matter to them when visiting their doctor or specialist. The Commission is also working to support clinicians to work in partnership with their patients. In collaboration with four specialist clinical colleges, we have completed work on education modules to assist clinicians to better communicate risk to consumers. These were released in the second half of 2017.The Commission has worked with the Australian Government and state and territory partners to incorporate quality and safety into hospital pricing and funding to improve patient health outcomes. The Commission, with clinicians, consumers and technical experts,   
is revising the national sentinel events list, developed a list of hospital-acquired complications and clinical conditions that could be considered as avoidable hospital readmissions. The COAG Health Council will oversee the continuing development, implementation and ongoing refinement of reforms to integrate safety and quality into the pricing and funding of public hospital services.

On 1 January 2017 the National General Practice Accreditation Scheme commenced. Developed by the Commission in conjunction with the Royal Australian College of General Practitioners (RACGP), the scheme offers greater choice to general practices seeking accreditation.

Finally, my thanks go to the Commission Board, health ministers, and health chief executive officers for their leadership. Thanks also to our Australian Government and state and territory partners, private sector colleagues, clinical and consumer advisors, and the outstanding staff of the Commission for our achievements this year.

# Strategic Plan 2016–2019

Report on performance

This section details the Commission’s achievements against its four priority areas. It also includes an overview of the state of safety and quality in Australian health care.

|  |  |
| --- | --- |
| Priority 1: Patient safety | 16 |
| Priority 2: Partnering with patients, consumers and communities | 33 |
| Priority 3: Quality, cost and value | 37 |
| Priority 4: Supporting health professionals to provide safe and high-quality care | 44 |
| The state of safety and quality in Australian  health care | 47 |
| Annual performance statements | 49 |

# Priority 1: Patient safety

|  |
| --- |
| This priority area aims to ensure patients and consumers are kept safe from preventable harm. |

## Implementation of the National Safety and Quality Health Service Standards

The primary aims of the National Safety and Quality Health Service (NSQHS) Standards are to protect the public from harm and to improve the quality of health service provision.

To meet the NSQHS Standards, health service organisations must implement organisation-wide safety and quality processes, along with a comprehensive clinical governance framework. This can reduce the risk of patient harm from hospital-acquired infections, medication errors, patient falls and errors at the transfer of care, and help prevent clinical deterioration and pressure injuries.

Health service organisations are currently assessed against the NSQHS Standards by any of nine approved accrediting agencies. Only health service organisations that demonstrate full compliance are awarded accreditation.

Assessment against the NSQHS Standards commenced in 2013. Since that time, 100% of Australian hospitals and day procedure services have implemented the NSQHS Standards and completed at least one accreditation cycle. As at 30 June 2017, 1,319 hospitals and day procedure services have been assessed to the NSQHS Standards.

During 2016–17, the Commission completed its annual comprehensive review of accrediting agencies, which included performance review meetings with each of the nine approved accrediting agencies.

The Commission’s Advice Centre provides health service organisations with support and guidance on the NSQHS Standards. In 2016–17, the Commission responded to 1,189 enquiries, including 986 email enquiries and 203 telephone enquiries. The Commission continued to meet its service delivery targets, responding to 95% of email enquiries within one business day and the remainder within five business days.

The National General Practice Accreditation Scheme, developed by the Commission in collaboration with the Royal Australian College of General Practitioners (RACGP), commenced on 1 January 2017. Four accrediting agencies were appointed by an industry-based approval panel in 2016 to assess general practices using the RACGP Standards for general practices.

The scheme offers general practices seeking accreditation greater choice of accrediting agency. It will also provide access to national de-identified data on the accreditation performance of general practices that are assessed.

Figure 1: Health service organisation accreditation 2016–17

This diagram shows that a total of 673 hospitals and day procedure services were assessed to the NSQHS Standards in 2016-17. 325 of those services were assessed to all 10 NSQHS Standards. 78% (253) met all core actions at initial assessment, while 22% (72) had to undergo a 90 day period of remediation.

348 services were assessed against Standards 1, 2 and 3 only for their mid-cycle assessment. 72% (249) met all core actions at initial assessment, while 28% (99) had to undergo remediation.

For all 673 health service organisations, all the core actions were met by the final assessment.

Table 1: Top core NSQHS Standards actions not met or met with merit

|  |  |
| --- | --- |
| Not met | |
| **3.10.2** | Compliance with aseptic technique is regularly audited |
| **1.18.2** | Mechanisms are in place to monitor and improve documentation of informed consent |
| **2.4.2** | Action is taken to incorporate consumers’ and/or carers’ feedback into publications prepared by the health service organisation for distribution to patients |
| **1.8.2** | Early action is taken to reduce the risks for at-risk patients |
| **3.16.1** | Compliance with relevant national or international standards and manufacturers’ instructions for cleaning, disinfection and sterilisation of reusable instruments and devices is regularly monitored |
| Met with merit | |
| **1.2.1** | Regular reports on safety and quality indicators and other safety and quality performance data are monitored by the executive level of governance |
| **1.1.2** | The impact on patient safety and quality of care is considered in business  decision-making |
| **1.2.2** | Action is taken to improve the safety and quality of patient care |
| **1.6.1** | An organisation-wide quality management system is used and regularly monitored |
| **1.6.2** | Actions are taken to maximise patient quality of care |

## Development of the NSQHS Standards (second edition)

The Commission commenced a review of the NSQHS Standards (first edition) in 2015. The objectives of the review were to ensure the NSQHS Standards reflect contemporary best clinical practice, and that only those actions that have improved patient outcomes were retained.

Following an initial national consultation process, the Commission developed a draft version of the second edition of the NSQHS Standards. This draft was refined following piloting and further sector-wide consultation, and was subject to a regulation impact statement.

In the second edition of the NSQHS Standards, the overall number of standards has been reduced from 10 to eight, and the number of actions has been reduced from 256 to 148.

The NSQHS Standards (2nd ed.) have been improved by:

* Reducing the duplication in the first edition of the NSQHS Standards
* Addressing safety gaps in the care of Aboriginal and Torres Strait Islander people, end-of-life care and the care of people with lived experience of mental illness or cognitive impairment
* Updating the evidence base

Adapting and clarifying the language to improve the applicability of the NSQHS Standards to a broader range of health service organisations.

The NSQHS Standards (2nd ed.) were endorsed by the Australian Health Ministers’ Advisory Council (AHMAC) in December 2016, and approved for release by the COAG Health Council in June 2017.

The Commission began developing resources to support the NSQHS Standards (2nd ed.) in 2016. It consulted with clinicians, consumers and content experts on the draft resources to ensure they meet the needs of target audiences, which include consumers, hospitals, day procedure services, multi-purpose services, small rural hospitals and governing bodies such as boards.

The Commission is also developing an interactive online resource for the NSQHS Standards (2nd ed.) that is designed to provide frontline clinicians, managers, and safety and quality coordinators with direct access to relevant information. The Commission expects that this resource will be available from   
mid-2018, and that its content will be expanded as the need for additional resources arises and new resources become available.

The Commission will launch the NSQHS Standards (2nd ed.) in November 2017, together with supporting resources and measures. Assessment to the NSQHS Standards (2nd ed.) will commence on   
1 January 2019.

|  |
| --- |
| Highlights |
| * Developed the NSQHS Standards (2nd ed.) * Attained the endorsement of the NSQHS Standards (2nd ed.) by COAG Health Council * Received 66 submissions in response to the consultation regulation impact statement, with 82% of respondents supporting the introduction of the NSQHS Standards (2nd ed.) * Completed consultation on draft resources to support the NSQHS Standards (2nd ed.), receiving 251 responses. |

## Revision of the Australian Health Service Safety and Quality Accreditation (AHSSQA) Scheme to improve the reliability of health service organisation accreditation processes

Health service organisations are assessed and accredited against the NSQHS Standards through the AHSSQA Scheme. The Commission is responsible for maintaining and coordinating this scheme.

To become accredited, health service organisations must pass assessments to show they have implemented the NSQHS Standards. The assessments are conducted by independent accrediting agencies, approved by the Commission, as part of the AHSSQA Scheme.

The awarding of accreditation status is meant to provide assurance to the community that the health service organisation meets expected patient safety and quality standards. While the NSQHS Standards have transformed standards from a managerial activity to an assessment of patient safety and quality, accreditation processes have not changed in over 40 years. The accreditation process must be subject to innovation if it is to meet its objective.

State and territory regulators and chief executives of health service organisations have expressed concerns that the accreditation process does not reliably verify that an organisation’s safety and quality systems are operational and effective. Concerns have also been raised that the NSQHS Standards and AHSSQA Scheme are open to interpretation by assessors. The most significant concerns relate to a number of hospitals that were awarded accreditation status when they clearly did not meet the NSQHS Standards, particularly Standard 1: Governance for Safety and Quality in Health Service Organisations.

To ensure the AHSSQA Scheme remains effective, significant revision of the accreditation process is required. Based on feedback received on the AHSSQA Scheme issues and possible solutions, the Commission will implement six strategies to improve the reliability of the accreditation process.The strategies include steps to:

* Improve the veracity of health service organisation assessments
* Improve the effectiveness and expertise of the assessment team
* Assess the health service organisation’s safety and quality data to better inform the assessment process
* Improve regulatory oversight
* Improve communications related to the assessments and their outcomes

Improve resources and support for health service organisations.

The Commission has begun initial consultation   
on revision of the AHSSQA Scheme, with most work to be completed in 2017–18. It will collaborate with health departments, health service organisations, approved accrediting agencies and consumers in developing and implementing these strategies.

|  |
| --- |
| Highlights |
| * Developed an implementation strategy to improve the reliability of health service organisation accreditation processes * Completed an initial consultation on the revision of the AHSSQA Scheme involving the nine approved accrediting agencies and the health departments of the Australian Government and state and territory governments * Conducted four literature reviews, covering the use of short-notice surveys, attesting, the assessment of safety and quality culture, and the use of patient journey methodology in accreditation. |

## Antimicrobial resistance, antimicrobial use, surveillance and healthcare-associated infections

In 2016–17, the Australian Government provided additional funding for the Antimicrobial Use and Resistance in Australia (AURA) Surveillance System. The AURA program continues to analyse and report on antimicrobial resistance and antimicrobial use in hospitals, aged care homes and the community through a range of surveillance programs.

AURA 2016: First Australian report on antimicrobial use and resistance in human health provides the most comprehensive picture of antimicrobial resistance (AMR), antimicrobial use, and appropriateness of prescribing in Australia to date. It sets a baseline that will allow trends to be monitored over time. AURA 2016 also highlights areas where future work will inform action to prevent the spread of AMR.

Comprehensive, coordinated and effective surveillance of AMR and antimicrobial use is a national priority. Surveillance is essential to understand the magnitude, distribution and impact of AMR and antimicrobial use, as well as to identify emerging issues and trends. It allows the early detection of critical antimicrobial resistances to ensure effective action can be taken, and provides information on the effectiveness of measures designed to promote appropriate use of antimicrobials and contain AMR. Surveillance is a critical component of Australia’s National Antimicrobial Resistance Strategy.

The AURA Surveillance System coordinates data from a range of sources and allows integrated analysis and reporting at a national level. The AURA Surveillance System brings together partner programs such as the Australian Group on Antimicrobial Resistance, the National Antimicrobial Prescribing Survey (NAPS), the National Antimicrobial Utilisation Surveillance Program (NAUSP) and Queensland Health’s OrgTRx system. Data is also sourced from the Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS), NPS MedicineWise, the National Neisseria Network, the National Notifiable Diseases Surveillance System, the Report on Government Services 2015 and Sullivan Nicolaides Pathology.

The AURA Surveillance System is providing critical information needed by clinicians, policymakers, researchers and health system managers to target efforts to inform antimicrobial stewardship and AMR policy and program development.

Following a six-monthly review in October 2016, the National Alert System for Critical Antimicrobial Resistances (CARAlert) was enhanced to enable state and territory health authorities to directly access CARAlert records for their jurisdiction, including the name of the public hospital where the isolate was collected. This information allows them to monitor the geographic distribution of critical antimicrobial resistances, and to liaise with hospitals to confirm infection control responses, as appropriate, in the event of an outbreak. Following the CARAlert upgrades, state and territory health departments can now generate local and national reports from the system. Direct access to CARAlert records is complemented by weekly national digest reports that include information on all critical antimicrobial resistances reported in the previous week, including the state or territory where the isolate was collected.

The Commission has a well-established national Healthcare-Associated Infection program that aims to prevent and contain antimicrobial

resistance through evidence-based infection control practices. In 2016–17, the Commission provided funding for a national hand hygiene program, and specified national definitions that allow infection rate trends to be monitored more effectively. The Commission also offered advice to improve practice through policy and guideline development, and provided national guidance on managing and measuring some emerging infections, which is key to preventing and containing antimicrobial resistance and surgical site infections.

|  |
| --- |
| Highlights |
| * Released AURA 2016: First Australian report on antimicrobial use and resistance in human health * Enhanced and expanded several components of the AURA program, including CARAlert, the National Passive Antimicrobial Resistance Surveillance System and the National Antimicrobial Utilisation Surveillance Program * Continued to publish detailed reports on each of the AURA surveillance programs and associated surveys * Released national guidance on carbapenemase-producing Enterobacteriaceae, the diagnosis and management of *Clostridium difficile*, and approaches to surgical site infection. |

## Mycobacterium chimaera and heater-cooler devices used in cardiac surgery

In 2015, the European Centre for Disease Prevention and Control issued an alert regarding seven cases of Mycobacterium chimaera infection that were associated with the use of certain heater-cooler devices during cardiac surgery. In each case, contaminated water from inside the heater-cooler device had been aerosolised into the operating room and appeared to contaminate the surgical field during an open-chest surgical procedure. Mycobacterium chimaera is a slow-growing bacterium that is rarely associated with human infection. The signs and symptoms of this infection can take up to five years to appear and are often difficult to differentiate from other illnesses. Treatment typically involves prolonged combination antibiotic therapy, while compromised valves and grafts may require surgical debridement or revision.

The likely contamination of these devices at the point of manufacture meant that Australian patients who were exposed to these devices were also at risk of infection. The Commission coordinated the national response to this infection risk. It also developed infection control guidance – most recently updated in February 2017 – to provide health service organisations with infection prevention and control strategies that minimise the risk of infection associated with these devices. This complemented other guidance produced by the Communicable Disease Network Australia and the Public Health Laboratory Network on case identification and laboratory testing methods.

The Commission worked closely with state and territory health departments, the private hospital sector and the Therapeutic Goods Administration to enable rapid information-sharing on case management and risk mitigation, and to monitor further developments in post-market surveillance of heater-cooler devices.

Despite additional cases being identified around the world after the initial outbreak in Europe, the risk of infection appears to be extremely low. Infections have been predominantly associated with cardiac surgery involving a prosthetic graft or the insertion of prosthetic material, such as a replacement valve. In Australia, as of June 2017, five patient cases have been identified and no patient deaths have been reported.

|  |
| --- |
| Highlights |
| * Worked with state and territory health departments and several national agencies to deliver a coordinated national risk mitigation response to the contamination of heater-cooler units * Published national guidance outlining infection prevention and control strategies to reduce the risk of infection for patients. |

## Digital patient safety

The Commission has conducted a clinical safety program for the My Health Record system since it was implemented in 2012.

In July 2016, the Australian Government established the Australian Digital Health Agency, giving it responsibility for the My Health Record system and national digital health infrastructure. The Agency appointed the Commission to operate a digital patient safety program. The Commission’s Digital Patient Safety Expert Advisory Group provided clinical guidance on identifying and prioritising areas for clinical safety reviews for the My Health Record system and national digital health infrastructure.

The program aims to provide My Health Record quality assurance and enhance the clinical safety of digital health services and systems. Program activities in 2016–17 included four clinical safety reviews of national digital health infrastructure and an analysis of consumer calls to the My Health Record helpline.

The Commission also initiated a ‘deep dive’ analysis of health identifier issues at the interface between the My Health Record system and the clinical systems that connect to it. This will be completed in August 2017.

Commission staff members co-chair the Agency’s medication safety, diagnostic imaging and pathology steering groups. The Commission also operated, on behalf of the Agency, a 24-hour My Health Record Clinical Incident Management Unit for the My Health Record system. In 2016–17, the unit responded to 24 incidents, providing rapid assessments of clinical safety risk and initiating interventions to address any clinical safety implications associated with the use of the My Health Record system.

The four clinical safety reviews undertaken during 2016–17 analysed:

* The adoption of national standardised terminology for allergies and alerts to determine uptake barriers and enabling factors
* The presentation of clinical documents in My Health Record to identify potential areas of improvement that could enhance both the user experience for clinicians and patient safety
* My Health Record system resilience and business continuity processes to identify enhancements that could improve system reliability
* Clinical functional assurance processes for new system releases to ensure appropriate functionality, optimal useability and enhanced patient safety.
* In addition to its work with the Agency, the Commission published two reports on health IT safety in 2016–17:
* Implementation of Electronic Medication Management Systems in Hospitals: A literature scan
* Literature Review and Environmental Scan on Approaches to the Review and Investigation of Health IT-Related Patient Safety Incidents.

To further support the safe implementation of digital health technology in Australia, the Commission published a report titled Barcoding and Other Scanning Technologies to Improve Medication Safety in Hospitals. This report provides evidence on how barcoding and scanning medicines reduces misidentification and medicine administration errors in hospitals. The Commission also developed and published the National Guidelines for On-Screen Presentation of Discharge Summaries, with funding from the Australian Government Department of Health. In addition, the Commission finished preparing the third edition of its Electronic Medication Management Systems: A guide to safe implementation and use, which was issued to state and territory health departments in July 2017.

|  |
| --- |
| Highlights |
| * Conducted four clinical safety reviews of the My Health Record system and national digital health infrastructure * Conducted an analysis of 50 helpline calls * Operated a 24-hour My Health Record Clinical Incident Management Unit, managing 24 incidents * Published national guidance to support the safe implementation of digital health systems in hospitals. |

## Patient safety in primary health care

Primary care services provide the first point of contact with the health system for the majority of Australians with a health concern. The primary care sector provides a range of services that help to prevent and manage acute and chronic conditions.1 These services are an important part of the Australian healthcare system, and a well-functioning primary care sector can improve the overall health of the population and reduce acute hospitalisations.2

Much of the evidence about patient safety comes from the acute sector. While some of the issues and risks raised in this evidence apply to primary care, there are also specific issues in this sector that need to be examined and addressed.

In November 2015, the Commission began a program of work to develop a nationally consistent and coordinated approach to improve patient safety and quality in primary care. The program will deliver a series of strategies, tools and resources on safety and quality that are specifically tailored for use in primary care.

In May 2016, the Commission established the Primary Care Safety and Quality Framework Committee to oversee the program and provide expert advice. The committee is made up of   
18 members from primary care stakeholder organisations and the Consumers Health   
Forum of Australia (CHF).

The following strategies have been identified as initial priorities for the Commission:

Developing a set of safety and quality standards for primary care settings based on the NSQHS Standards (2nd ed.)

Reviewing the Commission’s practice-level indicators for primary care as part of the development of an agreed data collection and reporting framework for the primary care sector.

The Commission is preparing a consultation paper to seek feedback from primary care stakeholders on other national improvement strategies that should be developed. The consultation paper is scheduled to be released by late 2017.

|  |
| --- |
| Highlights |
| * Established the Primary Care Safety and Quality Framework Committee to oversee the patient safety in primary health care program and provide expert advice * Began developing a set of NSQHS Standards for primary care settings and accreditation in primary care. |

## Medication safety

The Commission has stewardship of the standard tools used in Australian hospitals each day to prescribe, administer and dispense medicine safely. The Commission has maintained a series of nationally standardised medication charts for hospitals since 2007. Medication safety experts from around the country analyse issues logged by clinicians and provide guidance for use. The charts standardise the presentation of information on the intended use of medicines for an individual patient, as well as the presentation of medicines information in all high-risk healthcare settings. This reduces the risk of errors associated with prescribing, dispensing and administering medicines.

In July 2016, the Commission released the Pharmaceutical Benefits Scheme (PBS) Hospital Medication Chart, which enables prescribing and dispensing of medicines for patients on discharge. It also enables hospitals

or pharmacies to claim payment for those medicines under the PBS. This new medication chart is being used in the private hospital sector, and will also be used in public hospitals in most states and territories.

Online training modules were launched in 2017 to support the PBS Hospital Medication Chart and the National Inpatient Medication Chart. The Commission appointed NPS MedicineWise to develop and host the modules.

In January 2017, the Commission revised and published Recommendations for Terminology, Abbreviations and Symbols Used in Medicines Documentation.

Following scientific assessment by human factors experts, and piloting in six hospitals, a national subcutaneous insulin chart was issued for use in acute hospitals in May 2017. An insulin chart for sub-acute and mental health hospitals was issued to states and territories in July 2017.

In May 2017, the Commission published a report by the Sansom Institute for Health Research at the University of South Australia on mental health and medication safety. The report, Medication Safety in Mental Health, reviewed the literature, and identified areas and approaches for improving medicine management in mental health settings.

The Commission is committed to developing a national standard on dispense labelling for medicines in pharmacies. This standard is intended to improve the readability of medicine labels and the safety of patients in the community. An expert roundtable reviewed the draft standard in May 2017, and consumer testing of the prototype started in July 2017.

|  |
| --- |
| Highlights |
| * Released the PBS Hospital Medication Chart, along with training modules and materials * Released a national subcutaneous insulin chart for hospitals and an insulin chart for sub-acute and mental health hospitals * Revised *Recommendations for Terminology, Abbreviations and Symbols Used in Medicines Documentation* * Started developing a national standard on dispensing labels for medicines * Released a scoping study on medication safety in mental health settings. |

## National Patient Blood Management Collaborative

In 2015, the Commission led the National Patient Blood Management Collaborative, with funding from the Australian Government Department of Health. Twelve health service networks from across Australia participated in the Collaborative, which finished collecting data in March 2017. Its aim was to improve patient care and reduce the need for unnecessary transfusions by supporting improvements in the preoperative management of anaemia and iron deficiency for patients undergoing specific elective gastrointestinal, gynaecological and orthopaedic surgery procedures.

The Collaborative focused on the entire patient journey – from the time the need for surgery was identified through to surgery being performed – and recorded 12,648 patient episodes.The Commission led a series of learning workshops that allowed the participating health service teams to analyse and share data and to discuss their experiences of local quality-improvement processes. Workshop participants also consulted with experts in the field to gather new information and develop ideas for further clinical practice improvements. Interventions to manage iron deficiency included dietary therapy, oral iron supplements and administering intravenous iron in advance of surgery.

The Collaborative’s achievements included:

* Reducing red cell transfusions
* Improving the assessment and management of anaemia and iron deficiency before surgery across participating sites
* Improving the integration of care between primary and acute service systems, which provided better opportunities for continuity of care for elective surgery patients
* Helping to change clinical practice and workflows at the participating sites, which improved the overall management of elective patients.

|  |
| --- |
| Highlight |
| * Led the National Patient Blood Management Collaborative, which produced better outcomes for patients, reduced the use of transfusions and improved the coordination of care. |

## Mental health

The Commission has a strong commitment to improving the safety and quality of health services delivered to people with lived experience of mental health issues. One in five Australians experience mental health issues each year, and people with serious mental illness live on average 20 years less than the general population, largely due to preventable physical illness.

This year, the Commission undertook national consultation on the draft National Consensus Statement: Essential elements for recognising and responding to deterioration in a person’s mental state (the Consensus Statement). Stakeholders supported the approach taken in the Consensus Statement, which will be released in August 2017 following noting by AHMAC.

The consultation on the Consensus Statement highlighted the lack of any standardised mechanism for clinicians to monitor and track the signs of deterioration in a person’s mental state and integrate this with a person’s self-reported experience. The Commission has begun a project to develop consensus on how deterioration in a person’s mental state can be monitored and reported, which can then form the basis for health service organisations to develop their own local escalation protocols.

The Commission continues to work in partnership with other agencies. In 2016–17, this included participating in the consultation process for the draft Fifth National Mental Health and Suicide Prevention Plan and the National Mental Health Commission’s Equally Well Consensus Statement.

|  |
| --- |
| Highlights |
| * Finalised the National Consensus Statement: Essential elements for recognising and responding to deterioration in a person’s mental state * Contributed to the development of the Fifth National Mental Health and Suicide Prevention Plan. |

## Cognitive impairment

In 2016–17, the Commission continued to promote cognitive impairment as an important safety and quality issue through the Caring for Cognitive Impairment campaign. The campaign helps hospitals prepare for assessment to the NSQHS Standards (2nd ed.), which now includes specific items to improve care for people with cognitive impairment.

As of 30 June 2017, 1,564 individuals and 160 hospitals from across Australia have joined the campaign. The campaign is also being promoted by 31 supporting organisations. The campaign website has had 11,698 visits over 12 months, and more than 500 people have participated in five campaign webinars.

Within the broader Cognitive Impairment program, specific work related to antipsychotics is under way. The first Australian Atlas of Healthcare Variation identified high and variable rates in the prescription of antipsychotics for people aged 65 and over. These medicines may be appropriate for a small number of people; however, concerns have been raised that antipsychotics may be overused for behavioural control and sedation given that they have limited benefit and can cause significant harm, such as stroke, pneumonia, falls and fractures, and an increased mortality risk. The first-line response for older people with behavioural and psychological symptoms of dementia should be a person-centred, non-pharmacological approach with informed consent, unless the person is severely distressed and at immediate risk of harming themselves or others.

To identify key areas for action, the Commission held a national roundtable in October 2016. The purpose of the roundtable was to seek expert advice on ways to reduce the inappropriate use of antipsychotics in older people with behavioural and psychological symptoms of dementia, and to identify and prioritise strategies for action in the community, aged care homes and acute hospital settings. A second roundtable was held in May 2017 to consult specifically with primary care providers. The Commission is considering the outcomes of both roundtables and will release a summary report by August 2017 that includes an outline of the next steps to be taken.

|  |
| --- |
| Highlights |
| * Promoted the Caring for Cognitive Impairment campaign, with 160 hospitals, 1,564 individuals and 31 supporting organisations participating in the campaign * Commenced work on reducing the inappropriate use of antipsychotics in older people with behavioural and psychological symptoms of dementia. |

## Communicating for safety

Clinical communication is a key safety and quality issue. Communication failures, lack of team communication and inadequate documentation of clinical information are known to result in errors, misdiagnosis, inappropriate treatment and poor care outcomes.

In 2016–17, the Commission included actions in the NSQHS Standards (2nd ed.) to address clinical communication gaps, dedicating an NSQHS Standard specifically to communicating for safety. To support the implementation of the Communicating for Safety Standard, the Commission has drafted guides that will be finalised at the end of 2017 in consultation with the health sector.

The Commission has also published resources to support effective patient-clinician communication at transitions of care in hospitals. These include posters and information sheets for consumers, clinicians, senior executives and clinical leaders.

Recognising that effective communication is vital across the patient journey, the Commission has started developing a framework on communicating for safety. The framework identifies key stages in the patient journey where communication is essential for safe patient care. As part of the framework, the Commission will provide information and links to resources to support effective communication between clinicians, multidisciplinary teams and patients, as well as families and carers.

The Commission is also considering developing tools for junior clinicians that aim to translate current research on clinical communication into a useable and practical resource.

|  |
| --- |
| Highlights |
| * Included the Communicating for Safety Standard in the NSQHS Standards (2nd ed.) * Drafted guides to help large acute hospitals, small hospitals and day procedure services implement the Communicating for Safety Standard * Published resources on improving patient-clinician communication at transitions of care in hospitals * Started developing a framework on communicating for safety to support clinical communication across the patient journey. |

## Clinical governance framework

Since 2015, the Commission has completed reviews into identified patient safety problems for several state or territory health departments. These reviews have indicated that some health service organisations experience significant difficulties in implementing core clinical governance processes. These include issues with:

* Implementing an open disclosure response consistent with national and local standards
* Ensuring incident management and investigation systems can provide adequate surveillance for the purpose of recognising significant patient safety risks or failures
* Implementing corrective action in response to identified patient safety risks and failures
* Establishing complaint management systems that include a partnership with patients and carers
* Ensuring a robust and positive safety culture

Clearly understanding the roles and responsibilities of boards, executives, clinical teams and clinicians in clinical governance.

To address these issues, and to support the delivery of safe and high-quality health care and the best possible outcomes for patients, the Commission developed the National Model Clinical Governance Framework (the Clinical Governance Framework) for public and private healthcare organisations in the acute sector.

The Clinical Governance Framework is based on the NSQHS Standards (2nd ed.), particularly the Clinical Governance for Health Service Organisations and the Partnering with Consumers standards. As part of the NSQHS Standards as a whole, these standards, these standards constitute a complete and robust clinical governance framework.The Clinical Governance Framework will be released in August 2017. It will be supported by additional resources that the Commission has developed for specific target audiences, including clinicians, consumers and members of governing bodies such as boards.

|  |
| --- |
| Highlight |
| * Developed the National Model Clinical Governance Framework |

## Comprehensive Care Standard

As part of the review of the NSQHS Standards, the Commission set about identifying some of the common underlying clinical and systems issues that may place a person at risk of harm. Safety and quality gaps are frequently reported as failures to provide adequate care in specific situations or settings, or for specific conditions, or as failures to achieve expected outcomes in particular populations.

In 2016–17, the Commission, with its partners, developed the Comprehensive Care Standard, which has been included in the NSQHS Standards (2nd ed.). Comprehensive care is the coordinated delivery of the total health care required or requested by a patient. This care is aligned with the patient’s expressed care goals and healthcare needs, considers the impact of the patient’s health issues on their life and wellbeing, and is clinically appropriate regardless of whether the care trajectory is focused on recovery or end of life.

The purpose of the Comprehensive Care Standard is to address the cross-cutting issues that underlie many adverse events and to optimise health care while considering how risk and harm can be minimised along each patient journey. This requires a shift from focusing on specific errors and incidents to examining the origins of care failures within the cultural conditions and systems of a health service organisation. Inadequate risk assessment, goal setting and care planning can result in failures to deliver care that meets a person’s needs and is consistent with their preferences. The way that clinical teams operate and collaborate, and the way that work flow is coordinated and organised can have a significant impact on the delivery of safe and high-quality care.

In 2017, the Commission started developing a conceptual model for comprehensive care, and in 2017–18, the Commission will consult broadly on the model. This model supports the identification and development of tools and resources to help health service organisations deliver comprehensive care and meet the requirements of the NSQHS Standards (2nd ed.). This work includes scoping approaches for integrated screening and assessment.

|  |
| --- |
| Highlights |
| * Developed the Comprehensive Care Standard * Developed a model for supporting the delivery of comprehensive care, and started consultation on the tools and resources needed to support the delivery of comprehensive care, including tools for screening and assessment. |

## National safety and quality model for colonoscopy

The Australian Government Department of Health appointed the Commission to conduct a national consultation and develop a safety and quality model for colonoscopy. The appointment was made in the context of the anticipated growth in colonoscopy numbers from the planned expansion of the National Bowel Cancer Screening Program (NBCSP).

The model is intended to optimise the safety and efficacy of screening, diagnostic and therapeutic colonoscopies. A colonoscopy involves the endoscopic examination of the entire large bowel (from the rectum to the caecum) with a flexible endoscope. The distal portion of the small bowel (terminal ileum) may also be examined. The procedure is performed on adult, and less commonly paediatric, patients. It is the gold standard for investigating and managing large bowel pathology.

A screening colonoscopy is performed following a positive bowel cancer faecal occult blood test as part of surveillance for colorectal cancer. A diagnostic colonoscopy is used to investigate and diagnose other bowel conditions. A therapeutic colonoscopy is used to dilate strictures, place stents, decompress the colon, remove foreign bodies and polyps, and treat bleeding lesions.

Consultation on the safety and quality model for colonoscopy was completed in July 2016. The model that emerged from this process was reviewed by clinical colleges and societies, state and territory health departments, and the private hospital sector. It was then released for public consultation in August 2016.

The model requires health service organisations to demonstrate implementation of a clinical care standard for colonoscopy, certification and recertification of proceduralists, and local monitoring of a succinct set of quality indicators.

In 2017–18, the Commission will develop a clinical care standard for colonoscopy.

|  |
| --- |
| Highlight |
| * Developed a national safety and quality model for colonoscopy, with the support and endorsement of all clinical colleges and societies whose members perform colonoscopy. |

## Device safety

In 2016–17, state and territory health departments asked the Commission to examine two issues related to the safety of medicines and medical devices.

### Clearing house portal for medication alerts and medical device safety notifications

Medication alerts relate to the erroneous use of medicines (prescribing, dispensing or administering), which is typically caused by one or more contributing factors. Several issues relating to medical device errors have been raised with the Commission. A number of organisations issue safety alerts and advisories about the use of medicines and medical devices; however, there is no formal, coordinated method of sharing this information.

State and territory health departments asked the Commission to establish a web-based clearing house portal for medication alerts and medical device safety notifications, and to be responsible for its ongoing oversight and management.

The Commission established the clearing house portal in June 2017 to display medication and medical device alerts and advisories from each state and territory in one location. It complements existing national and international resources for medication and medical device alerts.

State and territory delegates access the clearing house portal via a secure, password-controlled section of the Commission’s website. Once they load an alert or advisory to the clearing house portal, all other delegates are informed via an automatically generated email. Each state and territory continues to issue alerts and advisories within their existing methods.

The Commission will generate routine and ad-hoc reports and summaries of the volume and nature of alerts and advisories.

### Small-bore connectors for liquids and gases in healthcare applications

In April 2016, the International Standard ISO 80369-6:2016, Small bore connectors for liquids and gases in healthcare applications – Part 6: Connectors for neuraxial applications, was published, specifying the design and dimensions of small-bore connectors intended for all neural applications. The standard aims to reduce the injection of erroneous substances via intrathecal, epidural and other neural routes.

State and territory health departments recommended that the Commission work with clinical groups to assess the standard’s fitness for purpose in Australia, and provide advice on its uptake and use in Australian hospitals.

The Australian and New Zealand College of Anaesthetists (ANZCA) and the Commission convened a roundtable on ISO 80369-6:2016 in August 2016. It was attended by representatives from peak clinical groups in Australia and endorsed ISO 80369-6:2016 as fit for purpose in Australia.

ANZCA and the Commission developed a joint position statement supporting ISO 80369-6:2016 as part of a global initiative to improve patient safety through reducing erroneous epidural and intrathecal injections. The statement recommends that devices incorporating small-bore connectors be classified and regulated in accordance with ISO 80369-6:2016, and specifies the planning required to implement neuraxial connectors safely.

The statement was issued to public and private sector health facilities and relevant professional bodies in June 2017.

|  |
| --- |
| Highlights |
| * Established a clearing house portal for medication alerts and medical device safety notifications * Held a roundtable on small-bore connectors for liquids and gases with ANZCA * Released a joint position statement with ANZCA on safe use of neuraxial connectors. |

# Priority 2: Partnering with patients, consumers and communities

|  |
| --- |
| The aim of this priority area is to ensure the health system enables patients, consumers and members of the com-munity to participate as partners with their health professionals in all aspects of health care |

## Person-centred healthcare systems

There is good evidence to show that using person-centred approaches to care can lead to better health outcomes, better patient experiences and greater efficiency. Delivering person-centred care allows consumers to have more control over treatment decisions, giving them a greater sense of ownership of their health.

The Commission is committed to supporting a health system in which patients, consumers and members of the community are treated as partners in all aspects of healthcare planning, design, delivery and evaluation. The Commission has been examining different ways to support the shift towards a more consistently person-centred healthcare system.

In 2016–17, the Commission integrated new requirements into the NSQHS Standards (2nd ed.) on partnering with consumers, both in governance and in care delivery. This involved developing a range of new actions and integrating person-centred principles across the NSQHS Standards (2nd ed.), with a particular focus on the Partnering with Consumers, Clinical Governance and Comprehensive Care standards.

The Commission also started work on identifying the common attributes or characteristics of high-performing person-centred healthcare organisations. In 2017, it conducted a series of interviews and site visits with high-performing international and Australian health service organisations, together with a literature review, to help identify these attributes and the actions that can be taken to foster them. In 2017–18, the Commission will use this work to develop guidance for health service organisations on fostering person-centred care.

|  |
| --- |
| Highlights |
| * Integrated person-centred actions and principles into the NSQHS Standards (2nd ed.) * Undertook interviews with Australian and international health service organisations, together with a literature review, to identify the key attributes of high-performing person-centred healthcare organisations. |

## Supporting consumers to be partners in their own care

Consumers are increasingly interested in acting as, and are being relied upon to act as, partners in the decision-making and delivery of their health care. The shift in community expectations about the way health care is delivered, together with the increasing proportion of people experiencing complex and chronic health conditions that need to be managed in the community, has strengthened the argument to better involve, activate and empower consumers to be partners in their own care.

Supporting consumers to be partners in their own care involves providing them with   
high-quality information about health and care, about the way the health system operates, and about safety and quality.

In 2016–17, the Commission published two reports exploring consumers’ needs and preferences for health information. The first report outlined the peer-reviewed literature in this area. The second report described the findings of a series of workshops and interviews with Aboriginal and Torres Strait Islander consumers, and separately with consumers from culturally and linguistically diverse backgrounds, on the types of health information that were important to them, and how they were best delivered. These reports will help the Commission develop guidance for health service organisations in 2017–18 on preparing health information for consumers.

The Commission also conducted extensive consultation and user testing for a consumer resource titled *Top tips for safe health care*. Released in April 2017, *Top Tips for Safe Health Care* provides information about some of the key things people should consider when thinking about their health care or interacting with the healthcare system. It provides tips, links to trusted health information sources and information about important safety issues.

|  |
| --- |
| Highlights |
| * Published a literature review on consumers’ needs and preferences in relation to health information * Published a report on the findings of research about the health information needs and preferences of Aboriginal and Torres Strait Islander consumers as well as consumers from culturally and linguistic diverse backgrounds * Released the *Top Tips for Safe Health Care* resource for consumers. |

## Shared decision making and health information

Shared decision making is a core part of enabling meaningful partnerships with consumers in their own care. It is a way of discussing and planning care that brings the consumer’s values, goals and concerns together with the best available evidence about treatment options, including benefits, risks and uncertainties. Shared decision making involves clinicians and consumers putting all considerations on the table, and making decisions about healthcare management together.

In late 2016, the Commission finalised and released three patient decision aids on the use of antibiotics for sore throats, middle ear infections and acute bronchitis. Clinicians and consumers can use these aids during a consultation to weigh up the risks and benefits of using antibiotics and make a decision together about what is best for them. In addition to these tools, the Commission has started work on developing decision support tools for osteoarthritis of the knee and heavy menstrual bleeding that will support implementation of the clinical care standards on these topics.

The Commission has, in partnership with the RACGP, completed an online education module on risk communication and shared decision making for general practitioners. The model has also been adapted for use by four additional colleges.

The Commission also developed and released, in partnership with Healthdirect Australia, an online tool for consumers called the Question Builder. This tool, which is freely available on the Healthdirect website, helps consumers prepare for a doctor’s appointment by building a list of questions they could ask their doctor, and considering the questions their doctor might ask them.

|  |
| --- |
| Highlights |
| * Tested and published three patient decision aids on the use of antibiotics for sore throats, middle ear infections and acute bronchitis * Developed and released an online education module on risk communication and shared decision making for general practitioners * Developed and released, in partnership with Healthdirect Australia, the online Question Builder to help consumers prepare a list of questions for medical appointments. |

## End-of-life care

Delivering high-quality end-of-life care is about ensuring that the consumer’s needs and preferences are understood and met. This requires a goal-directed and person-centred approach.

In 2016–17, the Commission consulted on, finalised and released the National Consensus Statement: Essential elements for safe and high-quality paediatric end-of-life care, which describes the core requirements for delivering safe and high-quality end-of-life care to

children in Australia. It is based on the National Consensus Statement: Essential elements for safe and high-quality end-of-life care, which was endorsed by health ministers in 2015.

The Commission also released a report on a pilot study, undertaken in partnership with Canberra Hospital, of an end-of-life care audit tool and staff survey. The audit and survey tools are aimed at providing data on the delivery of end-of-life care in hospitals and on staff perceptions of how it is delivered.

In 2016, following this pilot, the Commission commenced a validation study of the audit tool and survey, which are currently being tested in nine hospitals across Australia. The findings of this study will be published in 2017–18. The Commission is also developing an   
end-of-life care audit toolkit that will be made available to all health service organisations by early 2018.

In 2016–17, the Commission also published a literature review scoping existing indicators for end-of-life care in acute settings.

|  |
| --- |
| Highlights |
| * Released the National Consensus Statement: Essential elements for safe and high‑quality paediatric end‑of‑life care * Published the findings from a pilot study of an end-of-life care audit tool and survey in Canberra Hospital * Commenced a validation study of the audit tool and survey in nine hospitals across Australia * Scoped existing indicators for end-of-life care in acute settings. |

## National guidelines for on-screen presentation of medicines information for consumers

In October 2016, the Commission published the National Guidelines for *On-Screen Display of Consumer Medicines Information* (the Consumer Guidelines). This followed the release of the *National Guidelines for On-Screen Display of Clinical Medicines Information* (the Clinical Guidelines) in January 2016.

The Consumer Guidelines specify consistent and unambiguous terms for the display of medicines information in online information systems that are accessible to consumers. The Consumer Guidelines draw on the recommendations and rationales in the Clinical Guidelines. However, they also contain important exceptions and additions to reflect the needs of consumers when accessing electronic information about their medicines.As part of the development process, examples of on-screen medicines information were tested in a consumer focus group. The guidelines reflect the information needs and preferences broadly agreed upon.

The Commission is grateful to the Consumers Health Forum, the Australian Digital Health Agency and consumers in the focus group for their contributions to this work, and to the Australian Government Department of Health for its financial support.

|  |
| --- |
| Highlight |
| * Published national guidelines for the on-screen display of consumer medicines information. |

# Priority 3: Quality, cost and value

|  |
| --- |
| The aim of this priority area is to have a health system that provides the right care, minimises waste, and optimises value and productivity. |

## Identifying healthcare variation

Mapping variation is an invaluable tool for understanding how our healthcare system is providing care. Sometimes variation is expected, and even a good thing – for instance, when it reflects a response to differences in patient needs or patients’ choice of treatment options. However, differences in the use of health services that do not reflect these factors indicate what is known as ‘unwarranted variation’. Where unwarranted variation is thought to exist, it can be seen as an opportunity for the health system to improve. This improvement may involve increasing access to treatments that produce better outcomes for patients, or reducing access to treatments with little or uncertain benefit.

The Australian Atlas of Healthcare Variation, released in 2015, brought discussions about variation in health care into the mainstream in Australia. In response to the data and findings presented in the first Atlas, state and territory governments have been working to understand unwarranted variation by further analysing the data, and by working with clinicians to change models of care and the thresholds for interventions. Clinical colleges and societies are also investigating clinical variation within their specialties. The Commission has produced clinical care standards for several of the healthcare interventions that vary substantially in their use around the country.

The Commission launched the Second Australian Atlas of Healthcare Variation in June 2017. The second Atlas presents a clear picture of substantial variation in health care across Australia in areas such as chronic diseases, women’s health and surgical interventions.

Hysterectomy rates in Australia are seven times as high in the area with the highest rate compared to the area with the lowest rate. Overall, hysterectomies remain more common in Australia than in other developed countries. Endometrial ablation, a less invasive and often preferred alternative to hysterectomy for abnormal uterine bleeding, has very high rates of variation – 21 times as high in the area with the highest rate compared to the area with the lowest rate. These results suggest that not all women with abnormal uterine bleeding are aware of the treatment options available to them.

The second Atlas found hospitalisation rates for some common chronic conditions were up to 16 times as high in some local areas compared to others. These conditions included chronic obstructive pulmonary disease, diabetes complications, heart failure, cellulitis, and kidney and urinary tract infections. The high hospitalisation rates and substantial variations found for these conditions show that recommended care is not always provided for people with these conditions. They also indicate opportunities for improvement in the health system.

The second Atlas provides information on hospitalisation rates for Aboriginal and Torres Strait Islander people, as well as information on the percentage of services that are funded publicly and privately. It also includes analysis by socioeconomic status.

The Commission consulted widely to interpret the data in the second Atlas. Clinicians, policymakers, epidemiologists, researchers and consumers have helped to identify the likely drivers of variation for each type of hospitalisation examined, and most importantly, what needs to be done to improve care. The second Atlas contains a number of clear recommendations based on the best available evidence.

|  |
| --- |
| Highlights |
| * Acted on the recommendations of the first Atlas * Released the *Second Australian Atlas of Healthcare Variation*. |

Table 2: Second Australian Atlas of Healthcare Variation key findings and recommendations

| Area of variation | | | Recommendations |
| --- | --- | --- | --- |
| Hysterectomy (number of hospitalisations per 100,000 women aged 15 years and over, 2014–15) | | | 3a. The Medicare Benefits Schedule (MBS) Review Taskforce to ensure that MBS item descriptors relating to treatments for heavy menstrual bleeding are aligned with the care described in the Heavy Menstrual Bleeding Clinical Care Standard.  3b. State and territory health departments to ensure that women who have heavy menstrual bleeding have been offered clinically appropriate treatment options, as described in the Heavy Menstrual Bleeding Clinical Care Standard, before they are placed on a waiting list for hysterectomy.  3c. Relevant professional colleges to include intrauterine device insertion within their advanced training programs. They should also review incentives for clinicians to participate in continuing professional development training programs on intrauterine device insertion, and access to such programs, to increase the number of clinicians skilled in insertion of the levonorgestrel intrauterine system. |
|  | Rate (number per 100,000) | For people  living in... |
| Local area highest rate | 763 | Maryborough-Pyrenees (Vic) |
| Local area lowest rate | 115 | Gungahlin (ACT) |
| 6.6-fold difference | | |
| Endometrial ablation (number of hospitalisations per 100,000 women aged 15 years and over,  2012–13 to 2014–15) | | |
|  | Rate (number per 100,000) | For people  living in... |
| Local area highest rate | 390 | Burnie-Ulverstone (Tas) |
| Local area lowest rate | 19 | Fairfield (NSW) |
| 20.5-fold difference | | |
| Chronic obstructive pulmonary disease (number of potentially preventable hospitalisations per 100,000 people, 2014–15) | | | 1b. Local Hospital Networks, Primary Health Networks and the Aboriginal Community Controlled Health Service sector to promote appropriate care for the management of people with chronic obstructive pulmonary disease (COPD) using:  i. The COPD-X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease 2016 as the routine model of care |
|  | Rate (number per 100,000) | For people  living in... |
| Local area highest rate | 990 | Alice Springs (NT)\* |
| Local area lowest rate | 63 | Sherwood-Indooroopilly (Qld) |
| 15.7-fold difference | | |

\* Two local areas recorded higher rates but these are excluded from the fold difference as they need to be treated with caution.

|  |  |  |  |
| --- | --- | --- | --- |
| Area of variation | | | Recommendations |
|  | | | ii. Targeted anti-smoking programs in populations with high smoking rates, including areas with a high proportion of the population who are Aboriginal and Torres Strait Islander Australians, rural and remote areas, and areas of socioeconomic disadvantage.  1c. State and territory health departments to develop culturally appropriate pulmonary rehabilitation programs for Aboriginal and Torres Strait Islander Australians with COPD. |
| Diabetes complications (number of potentially preventable hospitalisations per 100,000 people, 2014–15) | | | 1e. Local Hospital Networks, Primary Health Networks and the Aboriginal Community Controlled Health Service sector to promote appropriate care for the management of people with diabetes using:  i. The guidelines General Practice Management of Type 2 Diabetes 2016–18 as the routine model of care  ii. The Australian National Diabetes Strategy 2016–2020 to ensure the provision of integrated models of care  iii. Performance management frameworks to assess compliance of care with relevant diabetes treatment guidelines. |
|  | Rate (number per 100,000) | For people living in... |
| Local area highest rate | 601 | Outback-North (Qld)† |
| Local area lowest rate | 52 | Manly (NSW) and Brisbane Inner‑West (Qld) |
| 11.6-fold difference | | |

† One local area recorded a higher rate but this is excluded from the fold difference as it needs to be treated with caution.

|  |  |  |  |
| --- | --- | --- | --- |
| Area of variation | | | Recommendations |
| Knee replacement (number of hospitalisations per 100,000 people aged 18 years and over, 2014–15) | | | 4a. The Medicare Benefits Schedule (MBS) Review Taskforce to ensure that MBS descriptors reflect the care described in the Osteoarthritis of the Knee Clinical Care Standard.  4b. State and territory health departments to use the Osteoarthritis of the Knee Clinical Care Standard to promote appropriate care for the management of people with knee pain, including conservative non-surgical management using a combination of non-pharmacological and pharmacological treatments.  4c. State and territory health departments to promote timely access to joint replacement or joint-conserving surgery when conservative management no longer provides adequate pain relief or maintenance of function. |
|  | Rate (number per 100,000) | For people living in... |
| Local area highest rate | 507 | Mid West (WA) |
| Local area lowest rate | 128 | Maribyrnong (Vic) and Darwin City (NT) |
| 4.0-fold difference | | |

## Improving appropriateness of care

Clinical care standards aim to support the delivery of appropriate care, reduce unwarranted variation in care and promote shared decision making between patients, carers and clinicians. Clinical care standards target key areas where opportunities exist to better align clinical practice with the best available evidence. They identify and define the care people should expect to be offered or receive, regardless of where they are treated in Australia.

During 2016–17, the Commission launched and broadly disseminated the Delirium, Hip Fracture Care and Osteoarthritis of the Knee clinical care standards.

In response to findings from the first Atlas and feedback from state and territory health departments, the Commission began developing the Heavy Menstrual Bleeding and Venous Thromboembolism Prevention clinical care standards in 2016–17. This included establishing expert topic working groups – made up of consumers, clinicians, researchers and nominated representatives from key health organisations or relevant technical experts – to inform the development of these new standards, which will be released in 2017–18.

In 2016, the Australian and New Zealand Hip Fracture Registry released its first annual report, which detailed patient and facility data. The release also coincided with the launch of the Hip Fracture Care Clinical Care Standard. Most of the indicators in the Hip Fracture Care Clinical Care Standard can be collected through this registry, which will assist in monitoring care in line with the standard. The Commission also released a document called Hip Fracture Care – The case for improvement.This is an educational resource designed to help clinicians and health service organisations implement the Hip Fracture Care Clinical Care Standard. Similarly, the Stroke Foundation conducts biennial audits into acute stroke care in line with the Acute Stroke Clinical Care Standard indicators.

A process has been developed to guide the review of clinical care standards. It will be piloted in 2017–18 using the initial clinical care standards released in 2014–15.

The Commission also finalised a framework to guide evaluation activities that measure the effectiveness of clinical care standards. Initial activities have commenced and will continue in the coming years.

|  |
| --- |
| Highlights |
| * Launched clinical care standards on delirium, hip fracture care and osteoarthritis of the knee * Started developing clinical care standards on heavy menstrual bleeding and venous thromboembolism prevention * Published *Hip Fracture Care – The case for improvement*, an educational resource designed to help clinicians and health service organisations implement the Hip Fracture Care Clinical Care Standard * Finalised a clinical care standards evaluation framework that will guide future activities. |

## Pricing for safety and quality

In April 2016, COAG signed a Heads of Agreement intended to form the basis of an addendum to amend elements of the National Health Reform Agreement for three years, until 30 June 2020. As part of this agreement, COAG resolved to develop, and begin to implement, reforms to improve health outcomes for Australians, and decrease avoidable demand for public hospital services.

Under the Heads of Agreement, states, territories and the Australian Government Department of Health agreed to work with the Independent Hospital Pricing Authority (IHPA) and the Commission to develop a comprehensive, risk-adjusted model that integrates quality and safety into hospital pricing and funding, and reduces avoidable hospital readmissions. This work has focused on pricing and funding for sentinel events, hospital-acquired complications and avoidable hospital readmissions.

The Commission’s involvement in this work has included:

* Reviewing the sentinel events list
* Curating the hospital-acquired complications list
* Providing clinical advice on risk adjustment for the hospital-acquired complications list
* Developing advice, in consultation with the states and territories, on a list of clinical conditions that can be considered avoidable hospital readmissions

Continuing to collaborate with IHPA.

For details on the Commission’s review of the sentinel events list and curation of the hospital‑acquired complications list, see ‘Minimising healthcare-related harm’ on page 45.

|  |
| --- |
| Highlights |
| * Provided advice to the Australian Health Ministers’ Advisory Council on a list of clinical conditions that can be considered avoidable hospital readmissions * Provided clinical advice on risk adjustment for the hospital-acquired complications list. |

# Priority 4: Supporting health professionals to provide safe and high‑quality care

|  |
| --- |
| The aim of this priority area is to have a health system that supports safe clinical practice by implementing robust and sustainable improvement systems. |

## Indicators and dataset specifications

In 2016–17, the Commission continued working on resources that outline best practice for developing and reviewing safety and quality indicators. This included completing the Toolkit for Developing Safety and Quality Indicators, which aims to provide best practice guidance on indicator and dataset development and review processes. The Commission’s Data Governance Framework and Data Plan 2016–2019 were also completed.

In 2016–17, the Commission continued developing and maintaining indicators and dataset specifications that helped improve safety and quality in health care. It developed and specified indicator sets to support the implementation of clinical care standards on osteoarthritis of the knee, delirium and heavy menstrual bleeding. The Commission is also researching and developing indicator sets for the clinical care standard on preventing venous thromboembolism.

The Commission completed specifications for defining and coding severe acute maternal morbidity during 2016–17, and continued to support data collection and reporting in relation to hand hygiene compliance. It has begun defining data models, tool specifications and indicator sets to increase the transparency of accreditation processes and outcomes. Work is underway to integrate post-partum haemorrhage indicators into national datasets.

Hospitals, states and territories, and private hospital ownership groups use the Core Hospital-Based Outcome Indicators (CHBOI) for routine local-level safety and quality reviews. To ensure the CHBOI are consistent with international methodological best practice, the Commission has progressed the development of the Australian Composite Model Hospital Standardised Mortality Ratio (ACM HSMR). This is a new model for measuring in‑hospital mortality.

In 2016–17, two jurisdictions piloted the ACM HSMR to assess its utility and functionality for monitoring safety and quality at the local level. Feedback was largely positive; however, issues requiring additional work still remain, including variation between the states and territories in data elements used in cohort specification and risk adjustment. This work will continue in 2017–18, with a view to incorporating the ACM HSMR into the CHBOI toolkit.

|  |
| --- |
| Highlights |
| * Created a toolkit for developing and reviewing safety and quality indicators * Continued developing and maintaining indicator sets for the clinical care standards, maternal morbidity, hand hygiene and accreditation * Continued developing and piloting the ACM HSMR. |

## Patient-reported experience measures

During 2016–17, the Commission developed and piloted a non-proprietary set of questions to facilitate national consistency in the way patients’ experiences are measured. These questions form a short measurement instrument known as the Australian Core Patient Experience Question Set (CorePEQS).

The consultative approach for the CorePEQS included conducting initial qualitative research with a group of 86 consumers drawn from each state or territory to define the factors that influence healthcare experiences. Seven more phases of qualitative and quantitative research followed. To establish the reliability and validity of the instrument, the Commission also conducted pilot testing in four states. Around 1,500 consumers participated in the pilot testing, which covered day and overnight settings in private and public hospitals.

The CorePEQS is due for release in September 2017, and will be available for use with day stay and overnight hospital patients free of charge.

|  |
| --- |
| Highlight |
| * Developed a non-proprietary instrument to measure patients’ experiences of health care in a consistent way nationally. |

## Minimising healthcare-related harm

Although most health care in Australia is associated with good clinical outcomes, preventable adverse events and complications continue to occur across the Australian healthcare system. To assist in identifying harm, the Commission’s work includes developing indicators for local monitoring of safety and quality.

### Hospital-acquired complications list

A hospital-acquired complication refers to a complication for which clinical risk-mitigation strategies may reduce (but not necessarily eliminate) the risk of that complication occurring. The hospital-acquired complications list was released in 2015. After the birth trauma and perineal laceration complications were included, the list was refined further and final specifications were released in October 2016.

In 2016–17, the Commission started developing supporting resources for the hospital‑acquired complications list with the aim of improving clinical documentation,   
and supporting local monitoring and quality improvement. This work will continue in   
2017–18. The Hospital-Acquired Complications Curation Clinical Advisory Group was convened to support this work and future refinements to the list.

### National sentinel events list

In 2016–17, the Commission continued its review of the national sentinel events list. The list comprises eight sentinel events – that is, adverse events that result in death or very serious harm to the patient. The Productivity Commission’s Report on Government Services details the number of sentinel events that occur each year. This is the first review of the list since 2004, when Australian health ministers introduced mandatory reporting on sentinel events.

The Commission also established the Sentinel Events Review Steering Committee to guide the revision of the list. The committee is made up of safety and quality experts from each state or territory, and a consumer representative. The Commission undertook significant clinical consultation in 2016–17 as part of the list redevelopment process. Open public consultation will take place in mid-2017,   
with a report to AHMAC scheduled for December 2017.

|  |
| --- |
| Highlights |
| * Released specifications for the national hospital-acquired complications list * Curated the hospital-acquired complications list * Established the Sentinel Events Review Steering Committee. |

## National clinical quality registries

Clinical quality registries collect, analyse and report on patient-related information to help improve the safety and quality of health care.

In 2016–17, the Commission continued working to implement the Framework for Australian Clinical Quality Registries. The framework, which was endorsed by AHMAC in 2014, specifies national arrangements under which peak clinical groups and health service organisations can work with governments to monitor and report on the quality (or appropriateness and effectiveness) of health care. In 2016–17, the Commission released two key reports on clinical quality registries:

* Economic Evaluation of Clinical Quality Registries. This evaluation of five clinical quality registries in Australia found that high‑quality clinical quality registries can improve clinical practice at a relatively low cost, leading to a significant net positive return on investment.
* Prioritised List of Clinical Domains for Clinical Quality Registry Development. This report documents the process of applying the AHMAC-endorsed prioritisation criteria to create a prioritised list of clinical domains that could potentially be developed into national clinical quality registries. The development of this list included analysing the available data and consulting with stakeholders.

|  |
| --- |
| Highlights |
| * Completed economic evaluations of clinical quality registries * Consulted on, and released a list of, high-priority clinical domains for the development of national clinical quality registries. |

# The state of safety and quality in Australian health care

|  |
| --- |
| As part of its legislative function, the Commission is required to report on the state of safety and quality in the Australian health system. |

Safety and quality is a complex field that is integrated into all aspects of health care. There are many people and organisations involved in ensuring that people receiving care in Australia are safe, and that they receive high-quality care. This means there is no single source of data that can provide comprehensive information about the safety and quality of the Australian healthcare system.

The Commission leads and coordinates national improvements in safety and quality, and part of its work relates to supporting better measurement to understand the state of safety and quality nationally, and also to enable local improvement. This section highlights some of the work the Commission is doing to support better understanding of the state of safety and quality in Australia.

The introduction of the NSQHS Standards gave a nationally consistent approach to safety and quality in Australia’s hospitals for the first time. The first edition of the NSQHS Standards included requirements for establishing an organisation‑wide quality management system that monitors and reports on safety and quality and informs improvements to patient care. These requirements have been strengthened in the second edition of the NSQHS Standards, with clear responsibilities for health service organisations to monitor performance, identify areas for improvement, implement improvement strategies, and provide reports on safety and quality performance. The governing body also has a clear responsibility to review reports, and monitor the organisation’s progress on safety and quality performance. These requirements will support the use of local data about safety and quality for improvement.

Another new action in the second edition of the NSQHS Standards is the requirement for health service organisations to monitor variation in practice against expected health outcomes, to provide feedback to clinicians on their variation, and to use information on unwarranted clinical variation to inform improvements in safety and quality. These new requirements were based on knowledge about the extent of variation in practice in Australia.

The first Australian Atlas of Healthcare Variation published in 2015 and the Second Australian Atlas of Healthcare Variation published in June 2017 indicate that there is substantial variation in clinical practice in many areas, including chronic disease, women’s health, some surgical and diagnostic interventions, and prescribing for a range of conditions. These findings have driven action by the Commission, state and territory governments, and clinical groups to reduce variation and improve appropriateness of care.

In April 2016 the Commission was asked by the COAG Health Council to work with the IHPA to examine ways to improve safety and quality by reducing avoidable hospital readmissions and integrating safety and quality into hospital funding and pricing. To do this, the Commission worked with clinicians, consumers, health service managers and policymakers to develop a set of hospital-acquired complications that can be used to report on the incidence, and in time, prevalence of patient safety events that may be prevented.These, and other sources of information such as the AURA Surveillance System, provide information about safety and quality that can inform local improvements, clinical responses, allocation of resources, and national policy. The Commission will continue to work collaboratively with its partners and stakeholders in providing a comprehensive picture of safety and quality in Australian health care.

A full report on key safety and quality themes can be found in the Commission’s publication *Vital Signs 2017: The state of safety and quality in Australian health care*.

# Annual performance statements

|  |
| --- |
| As the accountable authority of the Australian Commission on Safety and Quality in Health Care (the Commission), the Board presents the 2016–17 annual performance statements of the Commission, as required under paragraph 39(1)(a) of the *Public Governance, Performance and Accountability Act 2013*. In the opinion of the Board, based on advice from Commission management and the Audit and Risk Committee, these annual performance statements accurately reflect the performance of the Commission and comply with subsection 39(2) of the Public Governance, Performance and Accountability Act.    **Professor Villis Marshall AC** Board Chair |

## Entity purpose

The Commission was established in 2006 to lead and coordinate safety and quality improvements in health care nationally. The Commission contributes to better outcomes and experiences for patients, consumers and their carers, and improves productivity and sustainability of the Australian health system. The Commission has legislative responsibility for the National Safety and Quality Health Service (NSQHS) Standards, which are a major driver of safety and quality improvements within the health system.

The functions of the Commission are specified in the National Health Reform Act 2011 and are summarised as follows:

* Formulating standards, guidelines and indicators relating to healthcare safety and quality matters
* Advising health ministers on national clinical standards
* Promoting, supporting and encouraging the implementation of these standards and related guidelines and indicators monitoring the implementation and impact of these standards
* Promoting, supporting and encouraging the implementation of programs and initiatives relating to healthcare safety and quality matters
* Formulating model national schemes that provide for the accreditation of organisations that provide healthcare services and relate to healthcare safety and quality matters
* Collecting, analysing, interpreting and disseminating information relating to healthcare safety and quality matters
* Publishing reports and papers relating to healthcare safety and quality matters.

## Our performance

This year has been one of significant achievements for the Commission with the successful delivery of its *Health Portfolio Budget Statements 2016–17* targets and activities and the achievement of almost all key performance indicators (KPIs) for this period. The Commission fell just short of the required number of clinicians completing the   
healthcare-associated infection online education module. The Commission will develop strategies to ensure it meets this target in 2017–18.

The Commission continues to focus its work on areas that can best be improved through national action. Improvements to healthcare safety and quality are best achieved through national partnerships that are supported by local activities and implementation. The Commission achieves this through the maintenance of strong, positive relationships with its partners, including patients and consumers, consumer groups, healthcare providers, public and private healthcare organisations, governments and other healthcare organisations and agencies.   
The Commission works in partnership with its stakeholders to support the implementation of safety and quality initiatives through the development of guidance, resources, tools and educational material. The Commission supports the evaluation of its activities and measurement of the impact on the health system of safety and quality improvement initiatives. The Commission continually scans the horizon to identify new and emerging issues regarding safety and quality, while being responsive to the evolving needs of its stakeholders.There was no change to the framework in which the Commission operated in the 2016–17 reporting period, and no change to the Commission’s purposes, activities or organisational capability. The following examples highlight the key achievements of the Commission’s work for 2016–17 and demonstrate the benefits of this national approach:

* The implementation of the National Safety and Quality Health Service (NSQHS) Standards and the Australian Health Service Safety and Quality Accreditation (AHSSQA) Scheme continues to be a success. By 30 June 2017, all operating health service organisations in Australia to be assessed to the NSQHS Standards have now been assessed at least once, and an increasing number have received a second organisation-wide assessment.
* The second edition of the NSQHS Standards was finalised following extensive consultation. Following endorsement by Health Ministers, it will be released in November 2017 and assessment to the second edition will be required from January 2019.
* In 2016–17 the Commission started to examine the application of the NSQHS Standards in primary care, and a draft set of standards designed to support safety and quality in primary care will be released for consultation in mid-2017.
* The Second Australian Atlas of Healthcare Variation was launched in June 2017. The Atlas highlighted significant differences in treatment for the same conditions across the country in the areas of surgery, chronic disease and infection, women’s health, maternity and cardiovascular care. There has been significant progress in implementation of the recommendations from the first Atlas by the Commission, state and territory governments, local health services and clinical bodies. A report describing the impact of the first Atlas will be released in December 2017.
* The Commission released three clinical care standards in 2016–17 in the areas of hip fracture, delirium, and osteoarthritis of the knee. The clinical care standards identify and define the care people should expect to receive or be offered and can play an important role in delivering appropriate care and reducing unwarranted variation.
* Following establishment of the national surveillance system for antimicrobial resistance and antibiotic usage (AURA) in 2016, there has been a significant increase in participation across all elements of the system, with 159 hospitals now contributing information on antibiotic usage and 281 contributing information on appropriateness.
* The Commission continues to focus on improving safety and quality by developing tools and resources to support patients and consumers to be involved in their own care. In 2017, Top Tips for Safer Care and the Question Builder were released.
* In response to issues identified by the Commission in safety and quality reviews that have been carried out for the states and territories, the Commission has developed a national model clinical governance framework. The purpose of the framework is to ensure that patients and consumers receive safe and high-quality care by describing the elements that are essential for acute health service organisations to implement to achieve integrated corporate and clinical governance systems. It is based on the NSQHS Standards.

## Performance against the Health Portfolio Budget Statements and Corporate plan 2016–17

The Commission’s Corporate Plan 2016–17 was prepared under section 35(1) (a) of the Public Governance, Performance Accountability Act, and published in accordance with section 16E (3) of the Public Governance, Performance and Accountability Rule 2014. The Corporate Plan 2016–17 describes the planned program of work for the four-year period and specifies how the Commission will measure its performance during that period. The Corporate Plan 2016–17 can be accessed on the Commission’s website, at **www.safetyandquality.gov.au/about-us/corporate-plan/**

The Commission’s KPIs for the 2016–17 period were published in the Health Portfolio Budget Statements 2016–2017 and the Corporate Plan 2016–17. The following is a report of the Commission’s performance against these KPIs.

### Strategic Priority 1: Patient Safety

|  |
| --- |
| Qualitative performance criteria |

Successful implementation of the National Safety and Quality Health Service (NSQHS) Standards and ongoing monitoring of safety and quality performance of hospitals and day procedure services.

|  |
| --- |
| Criteria source |

Program 1.1, 2016–17 Health Portfolio Budget Statements, p.188; Corporate plan 2016–17, p.15.

|  |
| --- |
| 2016–17 performance target |

2016–17 Health Portfolio Budget Statement: 100% of hospitals and day procedure services assessed to the NSQHS Standards.

Corporate Plan 2016–17: Final draft version 2 of the NSQHS Standards (renamed the second edition of the NSQHS Standards).

|  |
| --- |
| Result against performance criteria |

The Commission continues to negotiate with states and territories on ongoing arrangements to support implementation of the NSQHS Standards in hospitals and day procedure services, community and other health services. The Commission uses performance data to identify safety and quality lapses by health services and negotiates with states and territories to implement remedial actions. The Commission will continue to provide national coordination and reforms of assessment processes with health system regulators, accrediting agencies and health services and amending the Australian Health Service Safety and Quality Accreditation (AHSSQA) Scheme. In 2016–17 the AHSSQA Scheme was reviewed and reformed to improve the performance of accrediting agencies and to address the performance issues identified by the health service organisations. The Commission also supports health services to meet the requirements of the NSQHS Standards and embed partnerships to support the next edition of the NSQHS Standards.

|  |
| --- |
| Result against performance target |

2016–17 Health Portfolio Budget Statements: 100% of all hospitals and day procedure services in Australia have been assessed to the NSQHS Standards.

Corporate Plan 2016–17: The Commission successfully submitted the final draft version of the NSQHS Standards to Australian Health Ministers’ Advisory Council and received unanimous approval from the Commonwealth, states and territories. The Commission is moving forward in 2017 to launch the second edition with associated documents, this is scheduled for November 2017.

|  |
| --- |
| Qualitative performance criteria |

Percentage of public hospitals meeting the benchmark for hand hygiene compliance.

|  |
| --- |
| Criteria source |

Program 1.1, 2016–17 Health Portfolio Budget Statements, p.188.

|  |
| --- |
| 2016–17 target |

Public hospitals meeting the benchmark of ≥75% for hand hygiene compliance.

|  |
| --- |
| Result against performance criteria |

Data reported by Hand Hygiene Australia confirms that public hospitals have met the benchmark hand hygiene compliance rates for the 2016–17 reporting period.

The overall compliance rates for each audit were above the listed target and are as follows:

Audit Period 1 — 2016: 84.1%

Audit Period 2 — 2017: 84.6%

Audit Period 3 — 2017: 84.3%

Further information can be found at   
**www.hha.org.au**

|  |
| --- |
| Quantitative performance criteria |

Number of clinicians completing the health care associated infection online education modules.

|  |
| --- |
| Criteria source |

Program 1.1, 2016–17 Health Portfolio Budget Statements, p.188.

|  |
| --- |
| 2016–17 target |

≥13 000 clinicians completing the   
healthcare-associated infection online education modules.

|  |
| --- |
| Result against performance criteria |

E3learning hosts the Commission’s   
healthcare-associated infection online education modules. Clinicians register for the online modules using an email address, which identifies them within the system.

In the 2016–17 financial year, 12,680 clinicians and students have registered and completed at least one of the modules. The figure falls just short of the target and the Commission will develop strategies to ensure the 2017–18 target is achieved.

|  |
| --- |
| Key performance indicator |

Develop and consult on a national model clinical governance framework.

|  |
| --- |
| Source |

Corporate Plan 2016–17, p. 16.

|  |
| --- |
| Result against the key performance indicator |

The Commission developed a draft national clinical governance framework and established an advisory committee to provide feedback and drive improvements of the document. The Commission has sought advice from jurisdictions, the private health sector, primary care committee and the Board. This advice has been used to revise the document and independent consultants have been hired to consult both internationally and domestically with key industry leaders.

|  |
| --- |
| Key performance indicator |

Review and revise reporting of antimicrobial resistance (AMR) and antimicrobial use (AU) to provide information and data to support jurisdictions and the private sector to implement strategies in infection control and AMR prevention and containment.

|  |
| --- |
| Source |

Corporate Plan 2016–17, p. 16.

|  |
| --- |
| Result against the key performance indicator |

The Commission has undertaken a broad range of activities to ensure a comprehensive approach to the availability of data and reports resulting from the antimicrobial use and resistance in Australia (AURA) Surveillance System. The AURA Coordination Unit has continued to work with its program partners to improve the breadth and utility of antimicrobial use (AU) and antimicrobial resistance (AMR) surveillance data for state and territory health departments, for the private sector and for the community more generally. These data provide the platform for better understanding of patterns of AU and AMR to inform strategies to improve prescribing, and to prevent and contain resistant organisms.

One of the newly established components of AURA, the operation of the national alert system for critical antimicrobial resistances (CARs), CARAlert has provided state and territory health departments with almost real-time access to surveillance data on CARs. The system offers significant opportunities for timely planning for response to potential outbreaks, where this action is required. The state and territory contact points also have direct access to CARAlert records for their state or territory, and details of public hospitals in their jurisdictions where the isolate in which a CAR was confirmed was collected. In the first year of operation 1,064 results from 73 originating laboratories across Australia were   
entered into the database.

This information allows states and territories to monitor the geographic distribution of CARs, to distribute the information to clinicians and health service managers and to liaise with hospitals to confirm an infection control response has been initiated. State and territory health authorities can also generate local and national reports from the system. Departments will be consulted shortly on local use of the system and further support that the AURA Coordination Unit could provide.

Work continues to focus on increasing the volume and representativeness of data for each of the components of the surveillance system, with increasing numbers of public and private hospitals participating in programs which provide valuable data on AMR and AU and the appropriateness of AU. The Commission will look in more detail at factors that drive variation in antimicrobial prescribing and use.

### Strategic Priority 2: Partnering with patients, consumers and communities

|  |
| --- |
| Qualitative performance criteria |

Provide safety and quality information to the general public.

|  |
| --- |
| Criteria source |

Program 1.1, 2016–17 Health Portfolio Budget Statements, p.188.

|  |
| --- |
| 2016–17 performance target |

Reporting in the Annual Report on the state of safety and quality in health care, and in the report for the general public, *Vital Signs 2016*.

Reporting to the general public through regular ACSQHC newsletters and website publications.

|  |
| --- |
| Result against performance target |

Vital Signs 2016 was published in October 2016. This Annual Report reports on safety and quality in health care at Chapter 2, Reporting on Performance.

The Commission regularly provides publications and updates via its website   
**www.safetyandquality.gov.au/** and via social media, such as twitter **(@ACSQHC**).

|  |
| --- |
| Key performance indicator |

Develop draft national statement, policy or framework on essential elements for a person centred healthcare system.

|  |
| --- |
| Source |

Corporate Plan 2016–17, p. 16.

|  |
| --- |
| Result against the key performance indicator |

Two reviews have been completed: an expert commentary on person-centred care and a review of person-centred care in the context of complex adaptive systems. Scoping has been undertaken and a draft report prepared identify-ing attributes of high-performing person-centred healthcare organisations. Interviews with high-performing person-centred Australian and international healthcare organisations have been conducted. This material will form the basis of a national approach to a person-centred healthcare system, and provide advice to health services about becoming high-performing person-centred services.

|  |
| --- |
| Key performance indicator |

Review of national and international literature and undertake environmental scan on patient safety models.

|  |
| --- |
| Source |

Corporate Plan 2016–17, p. 16.

|  |
| --- |
| Result against the key performance indicator |

In March 2017, the Commission completed a desktop review of national and international literature on patient safety models and an initial environment scan of international contemporary practice. This work will inform the development of a patient safety learning model in 2017–18, supported by further consultation to determine current state and territory practices, stakeholder perspectives on key elements and areas for future development.

### Strategic Priority 3: Quality, cost and value

|  |
| --- |
| Qualitative performance criteria |

Production of a Second Australian Atlas of Healthcare Variation covering topic areas agreed by Commonwealth, States and Territories.

|  |
| --- |
| Criteria source |

Program 1.1, 2016–17 Health Portfolio Budget Statements, p.189; Corporate Plan 2016–17, p. 17.

|  |
| --- |
| 2016–17 Reference point or target |

2016–17 Health Portfolio Budget Statements: Produce and disseminate new and updated maps of healthcare variations in Australia for a set of topic areas agreed by the Commonwealth, States and Territories by 30 June 2017.

Corporate Plan 2016–17: Publish second Australian Atlas of healthcare variation and develop an interactive web-based national Atlas of Healthcare Variation.

|  |
| --- |
| Result against performance criteria and target |

On 7 June 2017 the Commission successfully completed the launch of the Second Australian Atlas of Healthcare Variation, in collaboration with the Australian Government, state and territory governments, specialist medical colleges, clinicians and consumer representatives. This was the second time that data from the Medicare Benefits Schedule, Pharmaceutical Benefits Scheme and Admitted Patient Care National Minimum Data Set were all used to explore variation across different healthcare settings. The launch of the Second Australian Atlas of Healthcare Variation was accompanied by an online interactive platform of maps, available at **www.acsqhc.maps.arcgis.com/apps/MapAndAppGallery/index.html?appid=fd3b04ebe3934733b7ecb8514166c08f**

The successful launch of the second Atlas produced 49 recommendations that suggest ways in which coordinated action can be taken at all levels of the healthcare system. These are expected to be implemented across the Australian healthcare system over the coming years.

|  |
| --- |
| Qualitative performance criteria |

Develop Clinical Care Standards for consultation, informed by outcomes from the work on health care variation.

|  |
| --- |
| Criteria source |

Program 1.1, 2016–17 Health Portfolio Budget Statements, p.189; Corporate Plan 2016–17, p. 17.

|  |
| --- |
| 2016–17 Reference point or target |

2016–17 Health Portfolio Budget Statements: Clinical standards focusing on high-impact, high-burden and high-variation areas of clinical care are developed by 30 June 2017.

Corporate Plan 2016–17: National release of the clinical care standards developed in 2015–16, including those on hip fracture care, delirium and osteoarthritis of the knee.

|  |
| --- |
| Result against performance criteria and target |

In the Commission’s work plan 2016–17 it was decided that clinical care standards would be produced on delirium, hip fracture care and osteoarthritis of the knee by 30 June 2017.

By 30 June 2017, the Commission had launched clinical care standards on delirium, hip fracture care and osteoarthritis of the knee. The Commission has also commenced work on two clinical care standards, one on venous thromboembolism and another on heavy menstrual bleeding.

Hard-copy resources were made available to health services across Australia, professional colleges and organisations, and relevant consumer groups. They are also freely available on the Commission’s website at   
**www.safetyandquality.gov.au/acsqhc\_program/clinical-care-standards/**

### Strategic Priority 4: Supporting health professionals to provide safe and high‑quality care

|  |
| --- |
| Qualitative performance criteria |

Provide safety and quality information and resources to health professionals.

|  |
| --- |
| Criteria source |

Program 1.1, 2016–17 Health Portfolio Budget Statements, p.189;

|  |
| --- |
| 2016–17 Reference point or target |

Development and distribution of new/updated sector-specific implementation tools and resources for the public and private acute sector and primary care.

|  |
| --- |
| Result against performance criteria or target |

The Commission has provided safety and quality information and resources to health professionals in both the public and private acute sector and primary care, such as:

* Three clinical care standards (delirium, hip fracture and osteoarthritis of the knee)
* Medication charts
* Antimicrobial use and resistance data
* Audit tools covering a range of different safety and quality issues.

|  |
| --- |
| Qualitative performance criteria |

Condition-specific clinical indicator sets developed.

|  |
| --- |
| Criteria source |

Program 1.1, 2016–17 Health Portfolio Budget Statements, p.190.

|  |
| --- |
| 2016–17 target |

To develop two condition-specific clinical indicator sets.

|  |
| --- |
| Result against performance criteria or target |

In 2016–17, the Commission has developed and published three condition-specific indicator sets to accompany the clinical care standards on delirium, hip fracture and osteoarthritis of the knee.

Corporate governance and accountability

This section of the report outlines the Commission’s legislative requirements, corporate governance and accountability processes, including internal and external scrutiny arrangements and procedures for risk management and fraud control. It also includes profiles of the Commission’s Board and committee members.

|  |  |
| --- | --- |
| Legislation and requirements | 60 |
| Compliance with legislation | 60 |
| Strategic planning | 60 |
| Ministerial directions | 60 |
| Commission Board | 61 |
| Committees | 67 |
| Internal governance arrangements | 69 |
| External scrutiny | 70 |
| Developments and significant events | 70 |
| Environmental performance and ecologically sustainable development | 71 |
| Advertising and market research | 71 |
| National Health Reform Act amendments | 71 |
| Government policy orders | 71 |

# Legislation and requirements

The Commission is a corporate Commonwealth entity of the Australian Government, accountable to the Australian Parliament and the Minister for Health. The Commission’s principle legislative basis is the National Health Reform Act, which sets out its purpose, powers, functions, and administrative and operational arrangements. The National Health Reform Act also sets out the Commission’s Constitution, the process for appointing members of the Board and the Chief Executive Officer (CEO), and the operation of Board meetings.

The Commission must fulfil the requirements of the Public Governance, Performance and Accountability Act, which regulates certain aspects of Commonwealth entities’ financial affairs; their financial and performance reporting, accountability, banking and investment obligations; and the conduct of their accountable authorities and officials.

# Compliance with legislation

The Commission has complied with the provisions and requirements of:

* The Public Governance, Performance and Accountability Act
* The Public Governance, Performance and Accountability Rule
* Appropriation Acts

Other instruments defined as finance law, including relevant Ministerial directions.

The Commission did not have any significant non-compliance issues with finance law during the 2016–17 reporting period.

# Strategic planning

The Commission’s strategic plan describes the high-level priorities for the Commission over three to five years, and guides the development of detailed work plans.

The strategic plan covers four priority areas:

**1. Patient safety:** The aim of this priority area is to have a safe health system that minimises harm to patients and consumers, and reduces costs associated with preventable adverse events

**2. Partnering with patients, consumers and communities:** The aim of this priority area is to have a health system that maximises the potential for safe and high-quality care by supporting and encouraging patients, consumers and members of the community to participate as equal partners in health care

**3. Quality, value and cost:** The aim of this priority area is to have a health system that provides the right care to patients and consumers, improves health outcomes for patients and optimises the value of the healthcare system by improving productivity

**4. Supporting health professionals to provide safe and high-quality care:** The aim of this priority area is to have a health system that supports safe clinical practice by having robust and sustainable improvement systems.

# Ministerial directions

Section 16 of the National Health Reform Act empowers the Minister for Health to make directions with which the Commission must comply. The Minister for Health made no such directions during the 2016–17 reporting period.

# Commission Board

|  |
| --- |
| The Commission’s Board governs the organisation and is responsible for the proper and efficient performance of its functions. The Board establishes the Commission’s strategic direction, including directing and approving its strategic plan and monitoring management’s implementation of the plan. |

It also oversees the Commission’s operations and ensures that appropriate systems and processes are in place so that the Commission operates in a safe, responsible and ethical manner, consistent with its regulatory obligations.

The Board is established and governed by the National Health Reform Act and the Public Governance, Performance and Accountability Act.

## Board membership 2016–17

The Minister for Health appoints the Commission’s Board in consultation with all state and territory health ministers. The Board includes members who have extensive knowledge and experience in healthcare administration, the provision of health services, law, management, primary health care, corporate governance, and improving safety and quality.

### Professor Villis Marshall AC (Chair)

Professor Villis Marshall brings to the Board experience in providing healthcare services, managing public hospitals, and improving safety and quality. Professor Marshall has had significant clinical experience as a urologist, as Clinical Director (Surgical Specialties Service) for the Royal Adelaide Hospital and as Clinical Professor of Surgery at the University of Adelaide.

Professor Marshall was awarded a Companion of the Order of Australia (AC) in 2006 for services to medicine, particularly urology and research into kidney disease; to the development of improved healthcare services in the Defence forces; and to the community through distinguished contributions to the development of pre-hospital first aid care provided by St John Ambulance Australia.

His previous appointments include General Manager at Royal Adelaide Hospital, Senior Specialist in Urology and Director of Surgery at Repatriation General Hospital, and Professor and Chair of Surgical and Specialty Services at Flinders Medical Centre.

**Qualifications:** MD, MBBS, FRACS

**Board membership:** First appointed on 1 April 2012; appointed as Chair on 1 April 2013

### Mr Martin Bowles psm

Mr Martin Bowles was appointed Secretary of the Australian Government Department of Health on 13 October 2014.

Mr Bowles was previously the Secretary of the Department of Immigration and Border Protection. He has also been Deputy Secretary of the Department of Climate Change and Energy Efficiency, and Deputy Secretary of the Department of Defence. In 2012, Mr Bowles was awarded a Public Service Medal (PSM) for delivering highly successful energy efficiency policies and remediation programs for the Home Insulation and Green Loans programs.

Before joining the Australian Government, Mr Bowles held senior executive positions in the education and health portfolios in the Queensland and New South Wales public sectors. He is a Fellow of the Australian Society of Certified Practising Accountants.

**Qualifications:** BBus, GCPubSecMgmnt

**Board membership:** First appointed on 14 May 2015

### Dr David Filby psm

Dr David Filby has worked extensively across the Australian healthcare landscape in a number of significant policy and executive roles. He has held senior national health policy roles and senior executive positions in Queensland and South Australia. In July 2016 he completed a six-and-a-half-year term as Executive Consultant for SA Health and the Australian Health Ministers’ Advisory Council.

Dr Filby served on the board of the Australian Institute of Health and Welfare for 14 years and on the board of Helping Hand Aged Care Inc. for nine years, including six as Chair. He was also a board member of the National Health Performance Authority until June 2016, and previously served on the board of South Australia’s Child Health Research Institute Council. Dr Filby holds an Adjunct Professorship in the Faculty of Health Sciences at Flinders University. In 2007, he was awarded the Sydney Sax Medal by the Australian Healthcare and Hospitals Association, and in 2008, he received a PSM.

**Qualifications:** PhD

**Board membership:** First appointed on 29 July 2016

### Adjunct Professor John Walsh am

Professor John Walsh has expertise in social policy and funding for accident compensation, health and disability. He holds an Adjunct Professor appointment at the University of Sydney.

Professor Walsh is a board member of the National Disability Insurance Agency, having previously been a Productivity Commissioner. In 2010, he was part of the reference group that recommended a national disability insurance scheme.

Professor Walsh was the Deputy Chair of the National Health Performance Authority until June 2016, and chaired the independent panel overseeing Caring Together: The Health Action Plan for NSW. He has also held board memberships with several organisations including the NSW Motor Accidents Authority and NSW Home Care Service.

Professor Walsh was a partner at PricewaterhouseCoopers Australia, where he worked for 20 years. In 2011, he was appointed a Member of the Order of Australia (AM) and also received the Prime Minister’s Outstanding Achievement Award for service to the disability sector.

**Qualifications:** BSc, FIAA

**Board membership:** First appointed on 29 July 2016

### Professor Phillip Della

Professor Phillip Della has experience in public administration (health care), providing professional healthcare services, and improving safety and quality. Previously Deputy Pro Vice-Chancellor of Health Science at Curtin University, Professor Della continues to hold a number of positions at the university, including Professor and Head of the School of Nursing, Midwifery and Paramedicine.

Previous roles also include Chief Nursing Officer and Principal Nursing Advisor for the Western Australian Department of Health.

**Qualifications:** PhD, FACN

**Board membership:** First appointed on 1 April 2013; term concluded on 31 March 2017

### Ms Christine Gee

Ms Christine Gee brings to the Board extensive experience in private hospital administration, having held executive management positions for more than 25 years. She has been the Chief Executive Officer of Toowong Private Hospital since 1997. She is also Chair of the Commission’s Private Hospital Sector Committee.

Ms Gee is involved in numerous national and state boards and committees, including the Australian Private Hospitals Association, the Private Hospitals Association of Queensland, the Queensland Board of the Medical Board of Australia, and the Australian Government’s Second Tier Advisory Committee.

**Qualifications:** MBA

**Board membership:** First appointed as a Commission member in March 2006; appointed to the Board, as established under the National Health Reform Act, on 1 July 2011.

### Ms Wendy Harris qc

Ms Wendy Harris is a barrister who specialises in commercial law. She was admitted to the Victorian Bar in 1997 and was appointed Senior Counsel in 2010.

Between 2011 and 2015, she was Board Chair of the Peter MacCallum Cancer Centre, Australia’s only public hospital dedicated to cancer treatment, research and education. In addition to being a member of the Commission’s Board, Ms Harris chairs the National Model Clinical Governance Framework Advisory Panel.

Previous directorships include 10 years on the board of Barristers’ Chambers Limited, which is the repository of the Victorian Bar’s substantial property assets, and the provider of chambers accommodation and ancillary services for its members. Ms Harris is currently a member of the Bar Council of the Victorian Bar Inc.

**Qualifications:** LLB (Hons)

**Board membership**: First appointed in July 2015

### Dr Shaun Larkin

Dr Shaun Larkin worked for The Hospitals Contribution Fund of Australia (HCF), Australia’s largest not-for-profit health fund, from 1997 to 2017.

After serving as General Manager in a number of executive roles, including in strategic development, benefits management, corporate ventures and operations, he was selected as HCF’s Managing Director in 2009.

Before joining HCF, Dr Larkin was based in Singapore for four years, where he led the establishment of a chain of ambulatory medical centres throughout Asia.

Before this he worked for eight years as an executive for a large private hospital operator (Ramsay Health Care) in Australia and the United States.

**Qualifications:** HlthScD, MHSc, MBA, BHA

**Board membership:** First appointed on 1 April 2013

### Mrs Cheryle Royle

Starting her career as a nurse, Mrs Cheryle Royle has had a long career in health service management in both Victoria and Queensland. Mrs Royle was most recently the Chief Executive Officer of St Vincent’s Private Hospital Brisbane. She is a passionate advocate for quality care in hospitals, and has been on a number of boards in Victoria.

In 1998, Mrs Royle was recognised as the Telstra Victorian Business Woman of the Year for the private sector.

**Qualifications:** RN, RM, BN, GDip Nursing Administration

**Board membership:** First appointed on 4 September 2014

### Dr Helena Williams

Dr Helena Williams brings to the Board her clinical expertise as a general practitioner and as the previous Executive Clinical Director of Southern Adelaide-Fleurieu-Kangaroo Island Medicare Local Ltd. She is currently also the Presiding Member of the Southern Adelaide Local Health Network Governing Council.

Dr Williams’s previous board directorships include Cancer Council SA, Noarlunga Health Services, the South Australian Divisions of General Practice, the Australian General Practice Network and the Southern Adelaide Health Service.


**Qualifications:** MBBS, FRACGP

**Board membership:** First appointed as a Commission member in April 2008; appointed to the Board, as established under the National Health Reform Act, on 1 July 2011

## Board meetings and attendance

Table 3: Board meetings and attendance

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name | | Board meeting | | | | |
|  | 28 July 2016 | 14 September 2016 | 27 October 2016 | 24 February 2017 | 27 April 2017 |
| Professor Villis Marshallac (Chair)1 | |  |  |  |  |  |
| Mr Martin Bowles psm | |  |  |  |  |  |
| Adjunct Professor John Walsh am2 | |  |  |  |  |  |
| Dr David Filby psm | |  |  |  |  |  |
| Professor Phillip Della3 | |  |  |  |  |  |
| Ms Christine Gee2 | |  |  |  |  |  |
| Ms Wendy Harris qc4 | |  |  |  |  |  |
| Dr Shaun Larkin2 | |  |  |  |  |  |
| Mrs Cheryle Royle2 | |  |  |  |  |  |
| Dr Helena Williams2 | |  |  |  |  |  |



## Board development and review

New Board members undertake a formal induction to their role, including a meeting with the Chair and CEO. They receive an induction manual that includes the Board Operating Guidelines, which inform the conduct of Board members and describe their responsibilities and duties under legislation.

Board members are briefed on relevant topics at meetings as appropriate, and are required to undertake ongoing professional development relevant to, and in line with, the Commission’s needs. The Commission supports Board members to pursue these activities.

## Ethical standards

The Commission’s Board Operating Guidelines provide a Board Charter that outlines the function, duties and responsibilities of the Board, and a code of conduct that defines the standard of conduct required of Board members and the ethics and values they are bound to uphold. The Duty to Disclose Interests Policy for Board Members requires Board members to recognise, declare and take reasonable steps to avoid or appropriately manage any conflict of interest. This includes the duty to disclose material personal interests, as required under section 29 of the Public Governance, Performance and Accountability Act.

## Related-entity transactions

In accordance with the requirements prescribed by section 17BE of the Public Governance, Performance and Accountability Rule and the Department of Finance’s Resource Management Guide No. 136 – Annual reports for corporate Commonwealth entities, related‑entity transactions during 2016–17 are disclosed in Appendix C.

## Indemnity and insurance

The Commission holds directors’ and officers’ liability insurance cover through Comcover, the Australian Government’s self-managed fund.   
As part of its annual insurance renewal process, the Commission reviewed its insurance coverage in 2016–17 to ensure the coverage was still appropriate for its operations.

During the year, no indemnity-related claims   
were made, and the Commission knows of   
no circumstances likely to lead to such claims being made. Many liability limits under the Commission’s Schedule of Cover are standard Australian Government limits, such as $100 million in cover for general liability and professional indemnity, as well as directors’   
and officers’ liability. The Commission’s business interruption indemnity cover is for a period of up to 24 months. Motor vehicle, third-party property damage and expatriate cover have not been taken out, as they don’t apply to the Commission.

The Commission’s Board. Front row left to right: Professor Villis Marshall AC (Chair), Adjunct Professor John Walsh AM. Back row left to right: Ms Wendy Harris QC, Professor Phillip Della, Dr David Filby PSM, Ms Christine Gee,   
Dr Shaun Larkin and Mrs Cheryle Royle

# Committees

The Audit and Risk Committee advises the Commission and the Board on audit, risk and finance.

The Inter-Jurisdictional Committee meets regularly to provide advice to the Commission and the Board on the Commission’s work and safety and quality matters in the states and territories.

Additional standing committees and reference groups provide sector- and topic-specific advice on the Commission’s programs and projects.

## Audit and Risk Committee

The Board established the Audit and Risk Committee in compliance with section 45 of the Public Governance, Performance and Accountability Act and section 17 of the Public Governance, Performance and Accountability Rule. The committee is chaired by Ms Jennifer Clark. Ms Clark brings to the Audit and Risk Committee her extensive knowledge and experience in business, finance and governance through her career as a non-executive director since 1991 and as an investment banker for over 20 years.

The primary role of the Audit and Risk Committee is to help the Board discharge its responsibilities in relation to financial reporting, performance reporting, risk oversight and management, internal control, and compliance with relevant laws and policies. The committee’s responsibilities include:

* Monitoring the effectiveness of risk management frameworks, including identifying and managing the Commission’s business and financial risks, including fraud
* Monitoring the Commission’s compliance with legislation, including the Public Governance, Performance and Accountability Act and Rule
* Monitoring the preparation of the Commission’s annual financial statements and making a recommendation to the Board on their approval
* Reviewing the appropriateness of the Commission’s performance measures, and how these measures are assessed and reported
* Assessing whether relevant policies are in place to maintain an effective internal control framework, including for security arrangements and business continuity

Reviewing the work undertaken by the Commission’s outsourced internal auditors, including approving the internal audit plan and reviewing all audit reports and issues identified in those reports.

Board member Dr Shaun Larkin was appointed as a member of the Audit and Risk Committee in November 2016. Mr Trevor Burgess held the position of external member of the Audit and Risk Committee during 2016–17. Although members of the Commission’s senior management attended meetings as advisors, they were not members of the Audit and Risk Committee, which is in accordance with section 17 of the Public Governance, Performance and Accountability Rule.

The Audit and Risk Committee met five times during 2016–17. The Chair and members attended all relevant meetings.

## Inter-Jurisdictional Committee

The Inter-Jurisdictional Committee is made up of senior safety and quality managers from the Australian Government and state and territory governments. It is responsible for advising the Commission on policy development and facilitating jurisdictional engagement. The role of committee members is to:

* Advise the Commission on the adequacy of the policy development process, particularly policy implementation
* Ensure health departments and ministries are aware of new policy directions and able to review local systems accordingly
* Monitor national actions to improve patient safety, as approved by health ministers
* Help collect national data on safety and quality

Build effective mechanisms within jurisdictions to enable national public reporting.

The committee met five times during the 2016–17 financial year.

## Other committees and consultations

The Board has established two sub-committees that provide specific advice and support across all relevant areas of its work. These are the:

* Private Hospital Sector Committee

Primary Care Committee.

The Private Hospital Sector Committee is chaired by Ms Christine Gee and the Primary Care Committee is chaired by Dr Helena Williams.

The Commission also works closely with a number of time-limited expert committees, working parties and reference groups to inform and support its work. These groups allow the Commission to draw on expert knowledge, consult with relevant key stakeholders and develop appropriate implementation strategies.

The Commission consults widely with   
subject-matter experts, peak bodies, states and territories, consumers and other relevant individuals and organisations. This includes ongoing discussions with key national and other organisations, and with an extensive network of formal reference and advisory groups. These networks provide links with healthcare providers, consumers, subject-matter experts and state and territory representatives. The Commission also undertakes formal consultation on specific issues.

# Internal governance arrangements

The CEO manages the Commission’s day‑to‑day administration and is supported by an executive management team and internal management committees. The Commission’s internal governance arrangements include internal management, risk management, fraud control and internal audit.

## Internal management

The Commission has two internal management groups and three committees.

The Leadership Group and Business Group meet regularly to facilitate information sharing and help with decision-making.

The Work Health and Safety Committee develops and promotes strategies to support the health and safety of all employees and visitors. The Workplace Consultative Committee facilitates regular consultation and employee participation in the development and review of HR and operational policies and procedures. The Information and Records Management Steering Committee assesses the Commission’s record keeping, promotes good records management practices across the Commission and develops strategies to digitise the Commission’s records.

## Risk management

Risk management is part of the Commission’s strategy to promote accountability through good governance and robust business practices. The Commission is committed to embedding risk management principles and practices consistent with the Australian Standard AS/NZS ISO 31000:2009 Risk management – Principles and guidelines and the Commonwealth Risk Management Policy into its:

* Organisational culture
* Governance and accountability arrangements
* Reporting, performance review, business transformation and improvement processes.

Through the risk management framework and its supporting processes, the Commission formally establishes and communicates its approach to ongoing risk management, and helps employees accept and manage risks.

## Fraud control

The Commission recognises the responsibility of all Australian Government entities to develop and implement sound financial, legal and ethical decision-making. The Commission’s Fraud Control and Anti-Corruption Plan complies with the Attorney-General’s Commonwealth Fraud Control Policy. The plan minimises the potential for instances of fraud within the Commission’s programs and activities, whether committed by employees or people external to the Commission. Fraud risk assessments help the Commission understand fraud risks, identify internal control gaps or weaknesses, assessments are conducted regularly across the organisation, taking into consideration the Commission’s business activities, processes and accounts.   
The Commission also delivers fraud awareness training to staff members annually.

## Internal audit

Internal audit is a key component of the Commission’s governance framework, providing an ongoing independent appraisal of the organisation’s internal control systems. The internal audit process provides assurance that the Commission’s financial and operational controls can manage the organisation’s risks and are operating in an efficient, effective and ethical manner.

The Commission has appointed Crowe   
Horwath as its internal auditor. The firm   
provides assurance of the overall state of the Commission’s internal controls and advice on   
any systemic issues that require management attention.

# External scrutiny

External scrutiny of the Commission includes parliamentary and ministerial oversight, freedom of information and judicial decisions, and reviews by outside bodies such as the Commonwealth Ombudsman.

## Freedom of information

Agencies subject to the Freedom of Information Act 1982 are required to make information available to the public as part of the Information Publication Scheme (IPS). In accordance with Part II of the Act, each agency must display on its website a plan showing what information it publishes in accordance with the requirements of the scheme. The Commission’s plan and freedom of information (FOI) disclosure log are available on its website:   
**www.safetyandquality.gov.au**

See Appendix A for a table summarising FOI activities for 2016–17.

## Judicial decisions and reviews by external bodies

There were no judicial decisions or external reviews that significantly affected the Commission in 2016–17.

In 2016–17, there were no reports on the operations of the Commission by the Auditor‑General (other than the reports on financial statements), a parliamentary committee, the Commonwealth Ombudsman or the Office of the Australian Information Commissioner.

## Parliamentary and ministerial oversight

The Commission is a corporate Commonwealth entity of the Australian Government and part of the Health portfolio. As such, it is accountable to the Australian Parliament and the Minister for Health.

## Executive remuneration

Table 4: Remuneration paid to executives during 2016–17

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Total remuneration | Executives No. | Average Reportable Salary  $ | Average Contributed superannuation $ | Average Allowances $ | Average bonus paid $ | Average Total remuneration $ |
| $200000 and less | 1 | 59,207 | 6,785 | – | 26,137 | 92,130 |
| $200001 to $250000 | 0 | – | – | – | – | – |
| $250001 to $300000 | 1 | 219,413 | 39,106 | – | 25,549 | 284,068 |
| $300001 to $350000 | 1 | 234,190 | 40,187 | 424 | 26,765 | 301,565 |
| $350001 to $400000 | 0 | – | – | – | – | – |
| $400001 to $450000 | 1 | 388,770 | 27,695 | – | – | 416,465 |
| **Total number of executives** | **4** |  |  |  |  |  |

Note: Data does not include two individuals as they have not provided consent to disclose.

Table 5: Remuneration paid to highly paid staff during 2016–17

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Total remuneration | Executives No. | Average Reportable Salary  $ | Average Contributed superannuation $ | Average Allowances $ | Average bonus paid $ | Average Total remuneration $ |
| $200001 to $250000 | 2 | 165,964 | 28,503 | 142 | 20,040 | 214,649 |
| $250001 to $300000 | 3 | 210,115 | 36,955 | 213 | 27,580 | 274,863 |
| $300001 to $350000 | 2 | 244,316 | 41,948 | 578 | 28,072 | 314,913 |
| $350001 to $400000 | 0 | – | – | – | – | – |
| **Total number of executives** | **7** |  |  |  |  |  |

Note: Data does not include one individual as they have not provided consent to disclose.

# Developments and significant events

The Commission is required under subsection 19(1) of the Public Governance, Performance and Accountability Act to inform the responsible Minister and the Finance Minister of any significant decisions or issues that have affected or may affect its operations. In 2016–17, there were no such decisions or issues.

# Environmental performance and ecologically sustainable development

Section 516A of the Environment Protection and Biodiversity Conservation Act 1999 (EPBC Act) requires Australian Government organisations and authorities to include information in their annual reports about their environmental performance and contribution to ecologically sustainable developments. The Commission is committed to making a positive contribution to ecological sustainability. The Commission’s ecologically sustainable activities are detailed in Appendix B.

# Advertising and market research

Section 311A of the Commonwealth Electoral Act 1918 requires Australian Government departments and agencies to include in their annual reports particulars of any amounts over $13,000 that were paid to advertising agencies, market research organisations, polling organisations, direct mail organisations or media advertising organisations. The Commission made no such payments over $13,000 in 2016–17.

# National Health Reform Act amendments

No amendments were made to the National Health Reform Act during 2016–17.

# Government policy orders

No government policy orders applicable to the Commission were issued in 2016–17.

Our organisation

The Commission employs a diverse range of highly skilled professionals with experience across the healthcare industry. Because of the nature of its work, the Commission has a strong national presence in safety and quality in both the public and private sectors.

The Commission is committed to managing and developing its employees to achieve the objectives and outcomes contained in its work plan.

|  |  |
| --- | --- |
| Organisational structure | 74 |
| People management | 76 |
| Staff profile | 76 |
| Workplace health and safety | 77 |
| Learning and development | 77 |
| Disability strategy | 78 |
| Indigenous employment | 78 |

Figure 2: Organisational structure

# People management

The Commission continues to deliver high performance by providing ongoing support through its performance management systems and through embedding a strong sense of direction across the organisation. All employees are required to have an individual performance and development plan in place, and managers and employees have joint accountability for capability and career development.

The Commission participates in the online induction program offered by the Australian Public Service Commission (APSC), giving new employees the opportunity to learn how the Australian Public Service (APS) operates

and understand the behaviours expected of all staff members.

In May 2017, the Commission encouraged all staff members to participate in the APSC’s employee census survey.

# Staff profile

As of 30 June 2017, the Commission employed 79.3 full-time equivalent employees. Most employees are located in Sydney. The following table provides a breakdown of the Commission’s employee profile by classification, gender,   
full-time or part-time status, and ongoing or non-ongoing status.

Table 6: Employee profile as of 30 June 2017

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Classification | Female | | | | Male | | | | Total | |
| Ongoing | | Non-ongoing | | Ongoing | | Non-ongoing | |
| Full time | Part time | Full time | Part time | Full time | Part time | Full time | Part time |
| CEO |  |  | 1 |  |  |  |  |  | **1** |
| MO6 | 1 |  |  | 0.2 |  | 0.8 |  | 0.5 | **2.4** | |
| EL 2 | 9.4 | 2.8 | 1 |  | 5.6 | 0.6 |  |  | **19.4** | |
| EL 1 | 21.1 | 3.9 | 1 | 2.4 | 8 |  |  | 0.8 | **37.2** | |
| APS 6 | 9 | 1.4 | 1 |  | 2 |  |  |  | **13.4** | |
| APS 5 | 1 |  |  |  | 4 |  |  |  | **5** | |
| APS 4 | 1 |  |  |  |  |  |  |  | **1** | |
| **Total** | **42.5** | **8.1** | **4** | **2.6** | **19.6** | **1.4** | **0** | **1.3** | **79.3** | |

# Workplace health and safety

The Commission continues to promote a healthy and safe workplace and is committed to meeting its obligations under the Work Health and Safety Act 2011 and the Safety, Rehabilitation and Compensation Act 1988.

In 2016–17, the Commission implemented a revised work health and safety policy, new work health and safety procedures, and a new rehabilitation policy. All new staff members are required to complete work health and safety training as part of their induction.

The Commission undertook a number of activities during 2016–17 aimed at encouraging employees to adopt healthy work and lifestyle practices, including:

* Conducting ergonomic workstation assessments for new staff members and providing access to standing desk solutions
* Conducting biannual workplace inspections and encouraging all staff members to report incidents, accidents or hazards in the workplace
* Appointing new first aid officers, including one trained in mental health first aid
* Appointing new fire wardens
* Providing access to an employee assistance program
* Providing a resilience-building training session for all staff members
* Making influenza vaccinations available to all staff members
* Providing access to reimbursement of eyewear costs for use with screen‑based equipment.

There were 11 minor incidents reported in   
2016–17. There were no notifiable incidents in 2016–17. No notices were issued to the Commission and no investigations were initiated in 2016–17 under the Work Health and Safety Act.

# Learning and development

The Commission values the talents and contributions of its staff members and recognises the importance of building expertise and capability within the organisation.

Learning and development needs and opportunities are primarily identified through the performance development scheme. The Commission promotes learning and development by delivering regular continuing professional development sessions to all staff members.

During 2016–17, the Commission’s study support and training arrangements ensured the ongoing development of staff members’ skills and capabilities. Participation in study and training included 18 staff members accessing study support assistance and 38 staff members completing 49 external training courses. Commission staff members are currently undertaking a range of tertiary courses, including Master of Public Health, Master of Health Service Management and Master of Health Policy courses, and various graduate certificates in health-related fields.

# Disability strategy

In 2016–17, the Commission revised its workplace diversity program in accordance with APS strategies relating to Indigenous employment, disability employment and gender equality. The program provides a framework that enables the Commission to foster diversity and provide a safe, accessible and supportive working environment for all staff members.

The Commission is committed to increasing opportunities for people with a disability to participate in employment. The Commission complies with the Australian Government accessibility requirements for online access and publishing. Additionally, employees with a disability are provided with reasonable adjustments to help them perform their duties.

During 2016–17, the Commission participated in the APS Disability Champions Network.


# Indigenous employment

In 2016–17, the Commission did not meet its Indigenous employment target of 2.5% as it had no employees who identified as Indigenous.


The Commission is committed to improving the recruitment, retention and career development of Indigenous employees. The Commission undertook two recruitment processes for identified Indigenous roles during 2016–17. One role remains vacant while the other was filled through a secondment arrangement.

Financial statements

|  |  |
| --- | --- |
| Independent auditor’s report | 82 |
| Financial Statements | 84 |
| Notes to and forming part of the financial statements | 90 |







## Statement of Comprehensive Income

for the period ended 30 June 2017

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2017** | 2016 |  | | Original Budget  2017 | |  | | |
|  | **Notes** | **$'000** | $'000 |  | | $'000 | |  | | |
| **EXPENSES** |  |  |  |  | |  | |  | | |
| Employee benefits | [1.1A](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#'Note 3'!A1#'Note 3'!A1) | **12,206** | 12,179 |  | | 13,705 | | A | | |
| Suppliers | [1.1B](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#'Note 3'!A1#'Note 3'!A1) | **16,577** | 14,875 |  | | 7,727 | | B | | |
| Depreciation | 2.2A | **260** | 138 |  | | - | |  | | |
| **Total expenses** |  | **29,043** | 27,192 |  | | 21,432 | |  | | |
| **LESS:** |  |  |  |  | |  | |  | | |
| **OWN-SOURCE INCOME** |  |  |  |  | |  | |  | | |
| **Own-source revenue** |  |  |  |  | |  | |  | | |
| Rendering of services | [1.2A](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#'Note 4'!A1#'Note 4'!A1) | **10,789** | 12,408 |  | | 2,906 | | B,C | | |
| Interest | [1.2B](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#'Note 4'!A1#'Note 4'!A1) | **216** | 353 |  | | 200 | |  | | |
| External contributions | [1.2C](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#'Note 4'!A1#'Note 4'!A1) | **7,406** | 7,190 |  | | 7,406 | |  | | |
| **Total own-source revenue** |  | **18,411** | 19,951 |  | | 10,512 | |  | | |
| **Gains** |  |  |  |  | |  | |  | | |
| Reversal of provision | 1.2D | **-** | 250 |  | | - | |  | | |
| Resources received free of charge | 1.2E | **-** | 479 |  | | - | |  | | |
| **Total gains** |  | **-** | 729 |  | | - | |  | | |
| **Total own-source income** |  | **18,411** | 20,680 |  | | 10,512 | |  | | |
|  |  |  |  |  | |  | |  | | |
| **Net cost of services** |  | **10,632** | 6,512 |  | | 10,920 | | C | | |
|  |  |  |  |  | |  | |  | | |
| Revenue from Government | 1.2F | **10,920** | 7,190 |  | | 10,920 | | C | | |
| **Surplus** |  | **288** | 678 |  | | - | |  | | |
| **OTHER COMPREHENSIVE INCOME** |  |  |  |  | |  | |  | | |
| **Total other comprehensive income (loss)** |  | **-** | - |  | | - | |  | | |
| **Total comprehensive income (loss)** |  | **288** | 678 |  | | - | | D | | |
|  |  |  |  |  | |  | |  | | |
| The above statement should be read in conjunction with the accompanying notes. | | | | |  | |  | |  |
| **Original Budget Compared to 2017 Actual Variance Commentary**  **Statement of Comprehensive Income** | | | | | | | |  | |
| A Variance due to fewer staff transferring from the National Health Performance Authority (NHPA) to the Commission and also a reduction due to the average staffing level cap imposed by Department of Finance, not expected at the time of preparing the Portfolio Budget Statements (PBS).  B The budget reflects projects contracted at the time of preparing the PBS. The variance arises due to additional 2016-17 funding and project expenditure for projects contracted subsequent to preparation of the PBS.  C The PBS records a Grants Received total of $13.8m. This is comprised in the financial statements as Revenue from Government of $7.4m and $3.5m (see note 1.2) and Rendering of Services $2.9m. The Original Budget has been restated to reflect this.  D The budget is derived on a break even assumption. | | | | | | | | | |

## Statement of Financial Position

as at 30 June 2017

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **2017** | 2016 |  | Original Budget  2017 |  |
|  | **Notes** | **$’000** | $’000 |  | $’000 |  |
| **ASSETS** |  |  |  |  |  |  |
| **Financial Assets** |  |  |  |  |  |  |
| Cash and cash equivalents | [2.1A](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#RANGE!_Toc102541826#RANGE!_Toc102541826) | **6,333** | 10,851 |  | 9,089 | A, B |
| Trade and other receivables | [2.1B](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#'Note 7'!A1#'Note 7'!A1) | **1,858** | 2,182 |  | 2,838 | A |
| **Total financial assets** |  | **8,191** | 13,033 |  | 11,927 |  |
| **Non-Financial Assets** |  |  |  |  |  |  |
| Property, plant and equipment | [2.2A](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#'Note 8'!A1#'Note 8'!A1) | **138** | 398 |  | 44 |  |
| Other non-financial assets | clip_image001clip_image0012.2B | **530** | 391 |  | 207 | A |
| **Total non-financial assets** |  | **668** | 789 |  | 251 |  |
| **Total assets** |  | **8,859** | 13,822 |  | 12,178 |  |
| **LIABILITIES** |  |  |  |  |  |  |
| **Payables** |  |  |  |  |  |  |
| Suppliers | [2.3A](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#'Note 9'!A1#'Note 9'!A1) | **1,796** | 3,031 |  | 738 | A |
| Other payables | clip_image001clip_image001clip_image0012.3B | **1,773** | 5,827 |  | 7,565 | A, B |
| **Total payables** |  | **3,569** | 8,858 |  | 8,303 |  |
| **Provisions** |  |  |  |  |  |  |
| Employee provisions | 3.1 | **2,576** | 2,538 |  | 1,731 | A |
| Other provisions |  | **-** | - |  | 250 |  |
| **Total provisions** |  | **2,576** | 2,538 |  | 1,981 |  |
| **Total liabilities** |  | **6,145** | 11,396 |  | 10,284 |  |
| **Net assets** |  | **2,714** | 2,426 |  | 1,894 |  |
| **EQUITY** |  |  |  |  |  |  |
| Contributed equity |  | **1,836** | 1,836 |  | 1,836 |  |
| Reserves |  | **5** | 5 |  | 5 |  |
| Retained surplus |  | **873** | 585 |  | 53 | C |
| **Total equity** |  | **2,714** | 2,426 |  | 1,894 |  |
|  |  |  |  |  |  |  |
| The above statement should be read in conjunction with the accompanying notes. | | | | | |  |

|  |
| --- |
| **Original Budget Compared to 2017 Actual Variance Commentary**  **Statement of Financial Position**  A The budget reflects projects contracted at the time of preparing the PBS. The variance is due to the increase in actual activity compared to when the PBS was prepared.  B The variance arises due to the completion in 2016-17 of project work for which funding was received in advance. The completion of projects in 2016-17 has reduced the balance of cash and unearned income.  C The 2016-17 budget was derived on a break even assumption and an estimated carried forward surplus at the time of budget preparation. |

## Statement of Changes in Equity

for the period ended 30 June 2017

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **2017** | 2016 |  | Original Budget  2017 |  |
|  |  | **$’000** | $’000 |  | $’000 |  |
| **CONTRIBUTED EQUITY** |  |  |  |  |  |  |
| **Opening balance** |  | **1,836** | 1,836 |  | 1,836 |  |
| **Closing balance as at 30 June** |  | **1,836** | 1,836 |  | 1,836 |  |
|  |  |  |  |  |  |  |
| **RETAINED EARNINGS / (ACCUMULATED LOSSES)** |  |  |  |  |  |  |
| **Opening balance** |  | **585** | (93) |  | 53 | A |
| **Comprehensive income** |  |  |  |  |  |  |
| Surplus / (Deficit) for the period |  | **288** | 678 |  | - | A |
| **Total comprehensive income** |  | **873** | 585 |  | 53 | A |
| **Closing balance as at 30 June** |  | **873** | 585 |  | 53 | A |
|  |  |  |  |  |  |  |
| **ASSET REVALUATION RESERVE** |  |  |  |  |  |  |
| **Opening balance** |  | **5** | 5 |  | 5 |  |
| **Total comprehensive income** |  | **5** | 5 |  | - |  |
| **Closing balance as at 30 June** |  | **5** | 5 |  | 5 |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | |  | |
| **TOTAL EQUITY** |  |  |  |  |  | |  | |
| **Opening balance** |  | **2,426** | 1,748 |  | 1,894 | | A | |
| **Comprehensive income** |  |  |  |  |  | |  | |
| Surplus for the period |  | **288** | 678 |  | - | | A | |
| **Total comprehensive income** |  | **2,714** | 678 |  | - | |  | |
| **Transactions with owners** |  |  |  |  |  | |  | |
| **Contributions by owners** |  |  |  |  |  | |  | |
| Equity injection |  | **-** | - |  | - | |  | |
| **Total transactions with owners** |  | **-** | - |  | - | |  | |
| **Closing balance as at 30 June** |  | **2,714** | 2,426 |  | 1,894 | | A | |
|  |  |  |  |  |  | |  | |
| The above statement should be read in conjunction with the accompanying notes. | | | | | |  | |
|  | | | | | |  | |
| **Original Budget Compared to 2017 Actual Variance Commentary**  **Statement of Changes in Equity**  A The 2016-17 budget was derived on a break even assumption and an estimated carried forward surplus at the time of budget preparation. | | | | | |  | |

## Cash Flow Statement

for the period ended 30 June 2017

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2017** | 2016 |  | Original Budget  2017 | | |  | | |
|  | **Notes** | **$’000** | $’000 |  | $’000 | | |  | | |
|  |  |  |  |  |  | | |  | | |
| **OPERATING ACTIVITIES** |  |  |  |  |  | | |  | | |
| **Cash received** |  |  |  |  |  | | |  | | |
| Receipts from Government |  | **10,920** | 7,190 |  | 10,930 | | |  | | |
| State and Territory contributions |  | **7,406** | 7,190 |  | 7,406 | | |  | | |
| Rendering of services |  | **7,078** | 9,843 |  | 818 | | | A | | |
| Interest |  | **249** | 353 |  | 200 | | |  | | |
| Net GST received |  | **1,076** | 818 |  | 500 | | | A | | |
| **Total cash received** |  | **26,729** | 25,394 |  | 19,854 | | |  | | |
|  |  |  |  |  |  | | |  | | |
| **Cash used** |  |  |  |  |  | | |  | | |
| Employees |  | **(12,137)** | (11,972) |  | (13,705) | | | B | | |
| Suppliers |  | **(19,110)** | (16,812) |  | (8,149) | | | A | | |
| **Total cash used** |  | **(31,247)** | (28,784) |  | (21,854) | | |  | | |
| **Net cash used by operating activities** |  | **(4,518)** | (3,390) |  | (2,000) | | |  | | |
|  |  |  |  |  |  | | |  | | |
| **INVESTING ACTIVITIES** |  |  |  |  |  | | |  | | |
| **Cash used** |  |  |  |  |  | | |  | | |
| Purchase of property, plant and equipment |  | **-** | (13) |  | - | | |  | | |
| **Total cash used** |  | **-** | (13) |  | - | | |  | | |
| **Net cash used by investing activities** |  | **-** | (13) |  | - | | |  | | |
|  |  |  |  |  |  | | |  | | |
| **Net decrease in cash held** |  | **(4,518)** | (3,403) |  | (2,000) | | |  | | |
| **Cash and cash equivalents at the beginning of the reporting period** |  | **10,851** | 14,254 |  | 11,089 | | |  | | |
| **Cash and cash equivalents at the end of the reporting period** | [2.1A](file:///D:\DOCUME~1\johnni\LOCALS~1\Temp\notesBCBF1C\2012FinStats_Year%20End.xls#'Note 7'!A1#'Note 7'!A1) | **6,333** | 10,851 |  | 9,089 | | |  | | |
|  |  |  |  |  |  | | |  | | |
| The above statement should be read in conjunction with the accompanying notes. | | | | | | |  | | |
| **Original Budget Compared to 2017 Actual Variance Commentary**  **Cash Flow Statement**  A The budget reflects projects contracted at the time of preparing the PBS. The variance arises due to additional 2016-17 funding and project expenditure for projects contracted subsequent to preparation of the PBS.  B Variance arises due to fewer staff transferring from the NHPA to the Commission and also a reduction in the average staffing level cap imposed by Department of Finance, not expected at the time of preparing the budget. | | | | | |  | | |

## Table of Contents – Overview and Notes to the Financial Statements

Overview

1. Financial Performance
   1. Expenses
   2. Income
2. Financial Position
   1. Financial Assets
   2. Non-Financial Assets
   3. Payables
3. People and Relationships
   1. Employee Provisions
   2. Key Management Personnel Remuneration
   3. Related Party Disclosures
4. Managing Uncertainties
   1. Contingent Assets and Liabilities
   2. Financial Instruments
   3. Fair Value Measurement

## Overview

## Objectives of the entity

The Australian Commission on Safety and Quality in Health Care (the Commission) is an   
Australian Government controlled entity. It is a not-for-profit entity. The objective of the   
Commission is to lead and coordinate health care safety and quality improvements in Australia.

Initially established in 2006 by the Australian, State and Territory governments to lead and   
coordinate national improvements in safety and quality, the Commission’s permanent status was  
 confirmed with the assent of the National Health Reform Act 2011 (NHR Act). It is a   
Commonwealth Authority operating under the requirements of the Public Governance,   
Performance and Accountability Act 2013. The Commission commenced as an independent,   
statutory authority on 1 July 2011, funded jointly by the Commonwealth, State and Territory   
governments.

The Commission is structured to meet a single outcome:  
To improve safety and quality in healthcare across the health system, including through the   
development, support for implementation, and monitoring of national clinical safety and quality   
guidelines and standards.

The continued existence of the Commission in its present form and with its present programmes   
is dependent on Government policy and on continued funding from Parliament for the   
Commission’s administration and programmes.

### Basis of Preparation of the Financial Statements

The financial statements are general purpose financial statements and are required by   
section 42 of the Public Governance, Performance and Accountability Act 2013.

The financial statements have been prepared in accordance with:

1. *Public Governance, Performance and Accountability (Financial Reporting) Rule 2015   
   (FRR)* for reporting periods ending on or after 1 July 2015; and
2. Australian Accounting Standards and Interpretations – Reduced Reporting   
   Requirements issued by the Australian Accounting Standards Board (AASB) that apply   
   for the reporting period.

The financial statements have been prepared on an accrual basis and in accordance with the   
historical cost convention, except for certain assets and liabilities at fair value. Except where   
stated, no allowance is made for the effect of changing prices on the results or the financial   
position. The financial statements are presented in Australian dollars.

### New Accounting Standards

All new/revised/amending standards and/or interpretations that were issued prior to the sign-off date   
and are applicable to the current reporting period did not have a material effect on the   
Commission’s financial statements.

### Taxation

The Commission is exempt from all forms of taxation, except for Fringe Benefits Tax (FBT) and   
the Goods and Services Tax (GST).

### Budget Variances Commentary

The primary statements include commentary on comparisons between the original 2017 budget   
as presented in the 2016-17 Portfolio Budget Statements (PBS) to the Commission’s 2016-17   
financial outcome in accordance with Australian Accounting Standards. The budget has not been   
subject to audit.

## 1 Financial Performance

|  |  |  |
| --- | --- | --- |
|  | **2017** | 2016 |
|  | **$’000** | $’000 |
| 1.1 Expenses |  |  |
| 1.1A: Employee Benefits |  |  |
| Wages and salaries | **9,076** | 9,020 |
| Superannuation: |  |  |
| Defined contribution plans | **1,363** | 1,371 |
| Defined benefit plans | **259** | 241 |
| Leave and other entitlements | **1,449** | 1,442 |
| Other employee benefits | **59** | 105 |
| **Total employee benefits** | **12,206** | 12,179 |
|  |  |  |
| 1.1B: Suppliers |  |  |
| **Goods and services supplied or rendered** |  |  |
| Contracts for services | **10,672** | 10,238 |
| Travel | **795** | 956 |
| Information and communication | **950** | 683 |
| Printing and postage | **832** | 474 |
| Property outgoings | **424** | 162 |
| Other | **1,371** | 1,237 |
| **Total goods and services supplied or rendered** | **15,044** | 13,750 |
|  |  |  |
| **Goods and services supplied or rendered are made up of:** |  |  |
| Goods supplied | **857** | 542 |
| Services rendered | **14,187** | 13,208 |
| **Total goods and services supplied or rendered** | **15,044** | 13,750 |
|  |  |  |
| **Other supplier expenses** |  |  |
| Operating lease rentals |  |  |
| Minimum lease payments | **1,306** | 939 |
| Workers compensation expenses | **227** | 186 |
| **Total other supplier expenses** | **1,533** | 1,125 |
| **Total supplier expenses** | **16,577** | 14,875 |
|  |  |  |

|  |  |  |
| --- | --- | --- |
|  | **2017** | 2016 |
| **Leasing commitments** | **$’000** | $’000 |
| The Commission has a lease for Level 5 of 255 Elizabeth Street, Sydney.  The lease is due to expire 31 December 2017. |  |  |
|  |  |  |
| **Commitments for minimum lease payments in relation to non-cancellable operating leases are payable as follows:** |  |  |
|  |  |  |
| Within 1 year | **644** | 1,306 |
| Between 1 to 5 years | - | 664 |
| More than 5 years | - | - |
| **Total operating lease commitments** | **644** | 1,970 |
|  |  |  |
| **Accounting Policy**  Operating lease payments are expensed on a straight-line basis which is representative of the pattern of benefits derived from the leased assets. | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | **2017** | | | 2016 |
|  | | **$’000** | | | $’000 |
| 1.2 Income | |  | | |  |
| **OWN-SOURCE REVENUE** | |  | | |  |
| 1.2A: Rendering of Services | |  | | |  |
| Rendering of services | | **10,789** | | | 12,408 |
| **Total rendering of services** | | **10,789** | | | 12,408 |
|  | | | | | |
| **Accounting Policy**  Revenue from rendering of services is recognised by reference to the stage of completion of  contracts at the reporting date. The revenue is recognised when: a) the amount of revenue, stage of completion and transaction costs incurred can be   reliably measured; and b) the probable economic benefits associated with the transaction will flow to the  Commission.  The stage of completion of contracts at the reporting date is determined by reference to the proportion that costs incurred to date bear to the estimated total costs of the transaction.  Receivables for goods and services, which have 30 day terms, are recognised at the nominal  amounts due less any impairment allowance. Collectability of debts is reviewed at the end of  the reporting period. Allowances are made when collectability of the debt is no longer  probable. | | | | | |
| 1.2B: Interest | |  | | |  |
| Deposits | | **216** | | | 353 |
| **Total interest** | | **216** | | | 353 |
|  | |  | | |  |
| **Accounting Policy** | | |  | |  |
| Interest revenue is recognised using the effective interest method. | | |  | |  |
| 1.2C: External Contributions | |  | | |  |
| States and Territories contributions | | **7,406** | | | 7,190 |
| **Total external contributions** | | **7,406** | | | 7,190 |
|  | |  | | |  |
| **GAINS** | |  | | |  |
| 1.2D: Reversal of provision |  | | |  | |
| Reversal of provision | **-** | | | 250 | |
| **Total reversal of provision** | **-** | | | 250 | |
|  |  | | |  | |
| A provision for relocation was raised in 2014-15 as a result of advice received that the  Commission would be required to vacate the premises at the expiry of the lease on 31 December  2015. The Commission entered into a new lease arrangement on 1 January 2016 and the  provision was not required. | | | | | |

|  |  |  |
| --- | --- | --- |
|  | **2017** | 2016 |
|  | **$’000** | $’000 |
| 1.2E: Resources received free of charge |  |  |
| Resources received free of charge | **-** | 479 |
| **Total other gains** | **-** | 479 |
|  |  |  |
| Leasehold improvements (fit-out) at level 5, 255 Elizabeth Street were received free of charge  when the Commission commenced the new lease agreement on 1 January 2016. The gain  represents the fair value of the assets received. | | |
|  | | |
| **Accounting Policy**  Contributions of assets at no cost of acquisition or for nominal consideration are recognised as  gains at their fair value when the asset qualifies for recognition. | | |
| 1.2F: Revenue from Government |  |  |
| **Department of Health:** |  |  |
| Corporate Commonwealth entity payment item – Australian Health Ministers Advisory Council (AHMAC) | **7,406** | 7,190 |
| Corporate Commonwealth entity payment item – Smaller government measures | **3,514** | - |
| **Total revenue from Government** | **10,920** | 7,190 |
|  | | |
| **Accounting Policy**  Funding received or receivable from non-corporate Commonwealth entities (appropriated to  the Department of Health as a corporate Commonwealth entity payment item for payment to  the Commission) is recognised as Revenue from Government. | | |

## 2 Financial Position

|  |  |  |
| --- | --- | --- |
|  | **2017** | 2016 |
|  | **$’000** | $’000 |
| 2.1 Financial Assets |  |  |
| 2.1A: Cash and Cash Equivalents |  |  |
| Cash on hand or on deposit | **6,333** | 10,851 |
| **Total cash and cash equivalents** | **6,333** | 10,851 |
|  |  |  |
| 2.1B: Trade and Other  Receivables |  |  |
| **Good and services receivables:** |  |  |
| Goods and services | **1,434** | 1,806 |
| **Total goods and services receivable** | **1,434** | 1,806 |
| **Other receivables:** |  |  |
| Receivable from the Australian Taxation Office | **410** | 320 |
| Interest | **14** | 47 |
| Other | **-** | 9 |
| **Total other receivables** | **424** | 376 |
| **Total trade and other receivables (gross)** | **1,858** | 2,182 |
| **Total trade and other receivables (net)** | **1,858** | 2,182 |
| No receivables were impaired at 30 June 2017 (2016:  Nil). |  |  |
|  |  |  |
| **Accounting Policy**  *Receivables*  Trade receivables and other receivables that have fixed or determinable  payments that are not quoted in an active market are classified as ‘receivables’.  Receivables are measured at amortised cost using the effective interest method  less impairment. Interest is recognised by applying the effective interest rate.  *Impairment of Financial Assets*  Financial assets are assessed for impairment at the end of each reporting period. | | |

## 2.2 Non-Financial Assets

### 2.2A: Reconciliation of the opening and closing balances of property, plant and equipment

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Reconciliation of the opening and closing balances of property, plant and equipment  for 2017** | | | | | |
|  | **Leasehold improvement** | | **Plant and equipment** | | **Total** |
|  | **$’000** | | **$’000** | | **$’000** |
| **As at 1 July 2016** |  | |  | |  |
| Gross book value | **479** | | **103** | | **582** |
| Accumulated depreciation and impairment | **(119)** | | **(65)** | | **(184)** |
| **Net book value 1 July 2016** | **360** | | **38** | | **398** |
| Depreciation expense | **(240)** | | **(20)** | | **(260)** |
| **Net book value 30 June 2017** | **120** | | **18** | | **138** |
| **Net book value as of 30 June 2017 represented by:** | |  | |  | | |
| Gross book value | **479** | | **103** | | **582** |
| Accumulated depreciation and impairment | **(359)** | | **(85)** | | **(444)** |
|  | **120** | | **18** | | **138** |
| Leasehold improvements at Level 5, 255 Elizabeth Street previously belonging to the Office  of the Fair Work Ombudsman were received free of charge to the Commission on 1 January  2016 and have been recognised at fair value at 30 June 2017. | | | | | |

|  |
| --- |
| **Accounting Policy**  Assets are recorded at cost on acquisition except as stated below. The cost of acquisition  includes the fair value of assets transferred in exchange and liabilities undertaken. Financial  assets are initially measured at their fair value plus transaction costs where appropriate.  *Asset Recognition Threshold*  Purchases of property, plant and equipment are recognised initially at cost in the statement  of financial position, except for purchases of leasehold improvements costing less than  $50,000 and for all other purchased of property, plant and equipment costing less than  $5,000, which are expensed in the year of acquisition.  *Revaluations*  Following initial recognition at cost, property, plant and equipment are carried at fair value  less subsequent accumulated depreciation and accumulated impairment losses. Valuations  are conducted to ensure that the carrying amounts of assets do not differ materially from the assets’ fair values as at the reporting date. The regularity of independent valuations will  depend upon the volatility of movements in market values for the relevant assets.  Revaluation adjustments are made on a class basis. Any revaluation increment is credited to  equity under the heading of asset revaluation reserve except to the extent that it reversed a previous revaluation decrement of the same asset class that was previously recognised in  the surplus/deficit. Revaluation decrements for a class of assets are recognised directly in  the surplus/deficit except to the extent that they reversed a previous revaluation increment  for that class.  Any accumulated depreciation as at the revaluation date is eliminated against the gross  carrying amount of the asset and the asset restated to the revalued amount.  *Depreciation*  Depreciable property, plant and equipment assets are written-off to their estimated residual values over their estimated useful lives to the Commission using, in all cases, the straight- line method of depreciation.  Depreciation rates (useful lives), residual values and methods are reviewed at each reporting date and necessary adjustments are recognised in the current, or current and future  reporting periods, as appropriate.  Depreciation rates applying to each class of depreciable asset are based on the following  useful lives:  Asset Class 2017 2016  Leasehold improvements Lease term Lease term  Plant and equipment 5 years 5 years  *Impairment*  All assets were assessed for impairment at 30 June 2017. Where indications of impairment  exist, the asset’s recoverable amount is estimated and an impairment adjustment made if the  asset’s recoverable amount is less than its carrying amount.  The recoverable amount of an asset is the higher of its fair value less costs to sell and its  value in use. Value in use is the present value of the future cash flows expected to be  derived from the asset. Where the future economic benefit of an asset is not primarily  dependent on the asset’s ability to generate future cash flows, and the asset would be  replaced if the Commission were deprived of the asset, its value in use is taken to be its  depreciated replacement cost.  *Derecognition*  An item of property, plant and equipment is derecognised upon disposal or when no further  future economic benefits are expected from its use or disposal.  *Assets acquired at no cost*  Assets at no cost of acquisition or for nominal consideration are recognised at their fair value  when the asset qualifies for recognition. |

|  |  |  |
| --- | --- | --- |
|  | **2017** | 2016 |
|  | **$’000** | $’000 |
| 2.2B: Other Non-Financial Assets |  |  |
| Prepayments | **530** | 391 |
| **Total other non-financial assets** | **530** | 391 |
|  |  |  |
| No indicators of impairment were found for other non-financial assets. | |  |

### 2.3: Payables

|  |  |  |
| --- | --- | --- |
| 2.3A: Suppliers |  |  |
| Trade creditors and accruals | **1,796** | 3,031 |
| **Total supplier payables** | **1,796** | 3,031 |
|  |  |  |
| Settlement is usually made within 30 days. |  |  |
|  |  |  |
| 2.3B: Other Payables |  |  |
| Salaries and wages | **62** | 36 |
| Superannuation | **11** | 6 |
| Unearned income | **1,687** | 5,770 |
| Other | **13** | 15 |
| **Total other payables** | **1,773** | 5,827 |
|  |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 3 People and Relationships | | |  | | | |  | |
|  | | | **2017** | | | | 2016 | |
|  | | | **$’000** | | | | $’000 | |
| 3.1 Employee Provisions | | |  | | | |  | |
| Leave |  | | |  | | **2,576** | 2,538 | |
| **Total employee provisions** |  | | |  | | **2,576** | 2,538 | |
|  |  | | |  | |  |  | |
| **Employee provisions are expected to be settled in:** | | | | |  | | |  |
| No more than 12 months | |  | |  | | **1,513** | 1,532 | |
| More than 12 months | |  | |  | | **1,063** | 1,006 | |
| **Total employee provisions** | |  | |  | | **2,576** | 2,538 | |
|  | |  | |  | |  |  | |
| **Accounting Policy** | | | | | | | | |
| Liabilities for ‘short-term employee benefits’ and termination benefits expected within twelve  months of the end of the reporting period are measured at their nominal amounts.  *Leave* The liability for employee benefits includes provision for annual leave and long service leave.  The leave liabilities are calculated on the basis of employees’ remuneration at the estimated  salary rates that will be applied at the time the leave is taken, including the Commission's  employer superannuation contribution rates to the extent that the leave is likely to be taken  during service rather than paid out on termination.  The liability for long service leave has been determined by reference to the work of an  actuary as at 30 June 2017. The estimate of the present value of the liability takes into  account attrition rates and pay increases through promotion and inflation.  *Superannuation* The Commission's staff are members of the Commonwealth Superannuation Scheme (CSS),  the Public Sector Superannuation Scheme (PSS), the PSS accumulation plan (PSSap) or  other superannuation funds held outside the Australian Government.  The CSS and PSS are defined benefit schemes for the Australian Government. The PSSap  is a defined contribution scheme.  The liability for defined benefits is recognised in the financial statements of the Australian  Government and is settled by the Australian Government in due course. This liability is  reported by the Department of Finance’s administered schedules and notes.  The Commission makes employer contributions to the employees' defined benefit  superannuation scheme at rates determined by an actuary to be sufficient to meet the  current cost to the Government. The Commission accounts for the contributions as if they  were contributions to defined contribution plans.  The liability for superannuation recognised as at 30 June represents outstanding contributions. | | | | | | | | |

## 3.2 Key Management Personnel Remuneration

|  |  |  |
| --- | --- | --- |
| Key management personnel are those persons having authority and responsibility  for planning, directing and controlling the activities of the Commission, directly or  indirectly, including any director (whether executive or otherwise) of the  Commission. The Commission has determined the key management personnel to  be the Portfolio Minister, Chief Executive Officer, Chief Operating Officer, 5 Senior  Medical Officers and 10 Directors. Key management personnel remuneration is  reported in the table below: | | |
|  | **2017** | 2016 |
|  | **$’000** | $’000 |
|  |  |  |
| Short-term employee benefits | **1,526** | 1,469 |
| Post-employment benefits | **201** | 194 |
| Other long-term benefits | **132** | 121 |
| Termination benefits | **-** | - |
|  |  |  |
| **Total key management remuneration expenses1** | **1,859** | 1,784 |
|  |  |  |
| The total number of key management personnel that are included in the above  table are 17 (2016: 16). 2 directors included in this number waived their right or  were not eligible to receive remuneration during 2017 (2016: 3). The directors of the  Commission, including appointments and cessations during the year are listed in  note 3.3. | | |
| 1The above key management personnel remuneration excludes the remuneration  and other benefits of the Portfolio Minister. The Portfolio Minister's remuneration  and other benefits are set by the Remuneration Tribunal and are not paid by the  Commission. | | |

## 3.3 Related Party Disclosures

|  |  |  |
| --- | --- | --- |
| **Related party relationships**  The Commission is an Australian Government controlled entity. Related parties to this  entity are Directors, Key Management Personnel including the Portfolio Minister, and other  Australian Government entities. Directors of the Commission during the year were: | | |
|  |  |  |
|  | **Commenced** | **Ceased** |
| Professor Villis Marshall AC (Chair from 1 April 2013) | 1/04/2012 |  |
| Mr Martin Bowles PSM | 14/05/2015 |  |
| Professor Phillip Della | 1/04/2013 | 31/03/2017 |
| Christine Gee | 1/07/2011 |  |
| Ms Wendy Harris QC | 24/07/2015 |  |
| Dr Shaun Larkin | 1/04/2013 |  |
| Mrs Cheryle Royle | 14/05/2015 |  |
| Dr Helena Williams | 1/07/2011 |  |
| Dr David Filby | 29/07/2016 |  |
| Professor John Walsh AM | 29/07/2016 |  |
|  |  |  |
| **Transactions with related parties** |  |  |
| Given the breadth of Government activities, related parties may transact with the  government sector in the same capacity as ordinary citizens. Such transactions include the  payment or refund of taxes, receipt of a Medicare rebate or higher education loans. These transactions have not been separately disclosed in this note.  Several directors of the Commission hold directorships with other organisations. All  transactions between the Commission and organisations with a director common to the  Commission, or any dealings between the Commission and directors individually, are  conducted using commercial and arms-length principles. | | |
| The following transactions with related parties occurred during the financial year:   * Dr Helena Williams provided project support and expert advice to the Commission.  Fees paid by the Commission for these services were $5,339 (2016: $1,881). * A number of directorships expired on 31 March 2016 with several directors receiving reappointment on 29 July 2016. During the period when they were not directors, Dr.  Helena Williams ($1,742) and Christine Gee ($2,178) attended meetings on behalf of  the Commission for which they received fees paid in 2016-17. | | |

# 4 Managing Uncertainties

## 4.1 Contingent Assets and Liabilities

*Quantifiable Contingencies*

As at 30 June 2017, the Commission had no quantifiable contingencies (2015-16: nil).

*Unquantifiable Contingencies*

As at 30 June 2017, the Commission had no unquantifiable contingencies (2015-16: nil).

*Significant Remote Contingencies*

As at 30 June 2017, the Commission had no material remote contingencies (2015-16: nil).

## 4.2 Financial Instruments

|  |  |  |
| --- | --- | --- |
|  | **2017** | 2016 |
|  | **$'000** | $'000 |
| 4.2A: Categories of financial instruments |  |  |
| **Financial assets** |  |  |
| Cash on hand and at bank | **6,333** | 10,851 |
| Trade and other receivables | **1,448** | 1,862 |
| **Total financial assets** | **7,781** | 12,713 |
|  |  |  |
| **Financial liabilities** |  |  |
| **Financial liabilities measured at amortised cost:** |  |  |
| Trade creditors and accruals |  |  |
| Suppliers | **1,796** | 3,031 |
| **Total financial liabilities** | **1,796** | 3,031 |
|  |  |  |
| 4.2B: Net gains or losses on financial assets |  |  |
| Interest revenue | **216** | 353 |
| **Net gain from financial assets** | **216** | 353 |
|  |  |  |
| **Accounting Policy**  The Commission holds only cash and receivables as financial assets and trade creditors and  accruals as financial liabilities. Financial assets are recognised and derecognised upon trade  date. Supplier payables are recognised at amortised cost. Liabilities are recognised to the extent that the goods or services have been received (and irrespective of having been  invoiced).  *Effective Interest Method*  Income is recognised on an effective interest rate basis. | | |

### 4.3: Fair Value Measurement

|  |  |  |  |
| --- | --- | --- | --- |
| **Accounting Policy**  The Commission seeks independent valuation for material non-financial assets on a  triennial basis. The Commission procured the services of the Australian Valuation  Solutions (AVS) to undertake a comprehensive revaluation of the leasehold  improvement asset at 30 June 2016 and relied upon those outcomes to establish  carrying amounts. AVS provided written assurance to the Commission that the  models developed are in compliance with AASB 13. | | | |
|  |
|  | **Fair value  measurement at the  end of the reporting  period** | |
|  | **2017**  **$’000** | 2016  $’000 |
| **Non-financial assets** |  |  |
| Leasehold improvements | **120** | 360 |
| Plant and Equipment | **18** | 38 |
| **Total non-financial assets** | **138** | 398 |

The remaining assets and liabilities reported by the Commission are not measured at fair   
value in the statement of financial position.

Appendices

|  |  |
| --- | --- |
| Appendix A: Freedom of information summary | 108 |
| Appendix B: Compliance with ecologically sustainable development | 109 |
| Appendix C: Related-entity transactions | 110 |

# Appendix A: Freedom of information summary

The following table summarises the year’s freedom of information (FOI) requests and their outcomes, as discussed on page 70.

Table 7: Freedom of information summary 2016–17

|  |  |
| --- | --- |
| Activity | Number |
| **Requests** | |
| On hand as at 1 July 2016 | 0 |
| New requests received | 6 |
| Total requests handled | 5 |
| Total requests completed as at 30 June 2017 | 5 |
| Total requests on hand as at 30 June 2017 | 0 |
| **Action of request** | |
| Access granted in full | 2 |
| Access granted in part | 1 |
| Access refused | 2 |
| Access transferred in full | 0 |
| Request withdrawn | 1 |
| No records | 0 |
| **Response times** | |
| 0–30 days | 6 |
| 30–60 days | 0 |
| **Internal review** | |
| On hand as at 1 July 2017 | 0 |
| Requests received | 2 |
| Decision affirmed | 2 |
| Decision amended | 0 |
| Request withdrawn | 0 |
| **Review by the Administrative Appeals Tribunal** | |
| Applications received | 0 |
| **Review by the Office of the Australian Information Commissioner** | |
| Applications received | 0 |

## Appendix B: Compliance with ecologically sustainable development

|  |
| --- |
| The Commission is committed to making a positive contribution to ecological sustainability. The following table details the Commission’s activities in accordance with subsection 516A(6) of the Environmental Protection and Biodiversity Conservation Act 1999. |

Table 8: Summary of the Commission’s compliance with ecologically   
sustainable development

|  |  |  |
| --- | --- | --- |
| EPBC Act  requirement | Commission response | |
| The activities of the Commission during  2016–17 accord with the principles of ecologically sustainable development | | The Commission ensures its decision-making and operational activities mitigate environmental impact, with the principles of ecologically sustainable development embedded in the Commission’s approach to its work plan and in corporate, purchasing and operational guidelines. |
| Outcomes specified for the Commission in an Appropriations Act for 2016–17 contribute to ecologically sustainable development | | The Commission’s single appropriations outcome focuses on improving safety and quality in health care across the Australian health system. As such, the Commission does not directly contribute to ecologically sustainable development. |
| The effect of the Commission’s activities on the environment are documented | | The Commission’s offices are located across two 5-star (NABERS rating) buildings, with the Commission working proactively with building management to achieve energy savings where possible. The Commission continues to improve its use of electronic media to disseminate publications, reports and written materials to minimise its printing output. |
| Measures the Commission is taking to minimise its impact on the environment are identified | | The Commission is further reducing its environmental impact by improving its website functionality and increasing its use of multi-channel strategies to distribute information electronically. To reduce travel, the Commission uses remote meeting attendance options where feasible.  All staff members and visitors are expected to responsibly use and dispose of materials, as well as responsibly use electricity and water. |
| Mechanisms for reviewing and increasing the effectiveness of those measures are identified | | The Commission has a range of mechanisms for reviewing current practices and policies. In addition, staff members are encouraged to identify behavioural, procedural or policy changes that may reduce their environmental impact, and that of their team and the Commission more broadly. |

# Appendix C: Related-entity transactions

Table 9: Related-entity transactions during 2016–17

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vendor No. | Commonwealth Entity | Number of Transactions | Transaction Value | Description |
| 100362 | Department of Health | 11 | $596,225.90 | Payments processed in 2016–17 for corporate services received from the Department of Health under a shared services agreement between the Commission and Health |

Indexes and references

|  |  |
| --- | --- |
| Acronyms and abbreviations | 114 |
| Glossary | 116 |
| Index of tables | 119 |
| Index of figures | 119 |
| Compliance index | 120 |
| Index | 123 |
| References | 128 |

## Acronyms and abbreviations

|  |  |
| --- | --- |
| **AC** | Companion of the Order of Australia |
| **ACM HSMR** | Australian Composite Model Hospital Standardised Mortality Ratio |
| **AHMAC** | Australian Health Ministers’ Advisory Council |
| **AHSSQA Scheme** | Australian Health Service Safety and Quality Accreditation Scheme |
| **AM** | Member of the Order of Australia |
| **AMR** | Antimicrobial resistance |
| **ANZCA** | Australian and New Zealand College of Anaesthetists |
| **AO** | Officer of the Order of Australia |
| **APS** | Australian Public Service |
| **APSC** | Australian Public Service Commission |
| **AU** | Antimicrobial use |
| **AURA** | Antimicrobial Use and Resistance in Australia |
| **BBus** | Bachelor of Business |
| **BHA** | Bachelor of Health Administration |
| **BN** | Bachelor of Nursing |
| **BSc** | Bachelor of Science |
| **CARAlert** | National alert system for Critical Antimicrobial Resistances |
| **CHBOI** | Core Hospital-Based Outcome Indicators |
| **COAG** | Council of Australian Governments |
| **COPD** | Chronic obstructive pulmonary disease |
| **CorePEQS** | Australian Core Patient Experience Question Set |
| **FACN** | Fellow of the Australian College of Nursing |
| **FIAA** | Fellow of the Institute of Actuaries of Australia |
| **FRACS** | Fellow of the Royal Australasian College of Surgeons |
| **FRACGP** | Fellow of the Royal Australian College of General Practitioners |

|  |  |
| --- | --- |
| **GCPubSecMgmnt** | Graduate Certificate in Public Sector Management |
| **GDip** | Graduate Diploma |
| **HCF** | Hospitals Contribution Fund of Australia |
| **IHPA** | Independent Hospital Pricing Authority |
| **KPI** | Key performance indicator |
| **LLB** | Bachelor of Laws |
| **MBA** | Master of Business Administration |
| **MBS** | Medicare Benefits Schedule |
| **MBBS** | Bachelor of Medicine, Bachelor of Surgery |
| **MD** | Doctor of Medicine |
| **MHSc** | Master of Health Science |
| **NAPS** | National Antimicrobial Prescribing Survey |
| **NAUSP** | National Antimicrobial Utilisation Surveillance Program |
| **NBCSP** | National Bowel Cancer Screening Program |
| **NSQHS Standards** | National Safety and Quality Health Service Standards |
| **PBS** | Pharmaceutical Benefits Scheme |
| **PhD** | Doctor of Philosophy |
| **PSM** | Public Service Medal |
| **RACGP** | Royal Australian College of General Practitioners |
| **RM** | Registered midwife |
| **RN** | Registered nurse |
| **RPBS** | Repatriation Pharmaceutical Benefits Scheme |

# Glossary

|  |  |
| --- | --- |
| **Accreditation** | A status that is conferred on an organisation or individual when they have been assessed as having met particular standards. The two conditions for accreditation are compliance with an explicit definition of quality (that is, a standard) and passing an independent review process aimed at identifying the level of congruence between practices and quality standards. |
| **Adverse event** | An incident that results in harm to a patient or consumer. |
| **Antimicrobial** | A chemical substance that inhibits or destroys bacteria, viruses and fungi, including yeasts and moulds.3 |
| **Antimicrobial resistance** | A property of organisms – including bacteria, viruses, fungi and parasites – that allows them to grow or survive in the presence of antimicrobial levels that would normally suppress growth or kill susceptible organisms.3 |
| **Antimicrobial stewardship** | A program implemented in a health service organisation to reduce the risks associated with increasing antimicrobial resistance, and to extend the effectiveness of antimicrobial treatments. Antimicrobial stewardship may incorporate a broad range of strategies, including monitoring and reviewing antimicrobial use.3 |
| **Clinical care standards** | Standards developed by the Commission and endorsed by health ministers that identify and define the care people should expect to be offered or receive for specific conditions. |
| **Clinical communication** | The exchange of information about a person’s care that occurs between treating clinicians, the patient and members of a multidisciplinary team. Communication can take different forms, including face-to-face or electronic communication, or communication via telephone, written notes or other documentation. |
| **Clinical governance** | The set of relationships and responsibilities established by a health service organisation between its department of health (for the public sector), governing body, executive, clinicians, patients, consumers and other stakeholders to ensure good clinical outcomes. It ensures the community and health service organisations can be confident that systems are in place to deliver safe and high-quality health care and continuously improve services. |
| **Clinical handover** | The transfer of professional responsibility and accountability for some or all aspects of care for a patient, or group of patients, to another person or professional group on a temporary or permanent basis.4 |
| **Clinician** | A healthcare provider, trained as a health professional. Clinicians include registered and non-registered practitioners, or teams of health professionals, who spend the majority of their time delivering direct clinical care. |

|  |  |  |  |
| --- | --- | --- | --- |
| **Cognitive impairment** | | Deficits in one or more of the areas of memory, communication, attention, thinking and judgement. Cognitive impairment can be temporary or permanent, and can affect a person’s understanding, their ability to carry out tasks or follow instructions, their recognition of people or objects, how they relate to others and how they interpret the environment. Dementia and delirium are common forms of cognitive impairment seen in hospitalised older patients.5 Cognitive impairment can also be caused by a range of other conditions, such as an acquired brain injury, a stroke, intellectual disability or drug use. | |
| **Consumers** | | A person who has used, or may potentially use, health services. A healthcare consumer may also act as a consumer representative to provide a consumer perspective, contribute consumer experiences, advocate for the interests of current and potential health service users, and take part in decision-making processes.6 | |
| **Core Hospital-Based Outcome Indicators (CHBOI)** | | A succinct set of indicators that hospitals routinely monitor and review. These hospital-based outcome indicators can be generated by state or territory health authorities or private hospital owners that hold the source data and reported back to the facilities that provide healthcare services. | |
| **Delirium** | | An acute disturbance of consciousness, attention, cognition and perception that tends to fluctuate during the course of the day. Delirium is a serious condition that can be prevented in 30–40% of cases, and should be treated promptly and appropriately. Hospitalised older people with existing dementia are at the greatest risk of developing delirium. Delirium can be hyperactive (the person has heightened arousal, or can be restless, agitated and aggressive) or hypoactive (the person is withdrawn, quiet and sleepy).7 | |
| **Electronic medication management system** | | Enables medicines to be prescribed, dispensed, administered and reconciled electronically. | |
| **End of life** | | The period when a patient is living with, and impaired by, a fatal condition, even if the trajectory is ambiguous or unknown. This period may be years in the case of patients with chronic or malignant disease, or very brief in the case of patients who suffer acute and unexpected illnesses or events such as sepsis, stroke or trauma.8 | |
| **Hand hygiene** | | A general term referring to any hand-cleansing action. | |
| **Healthcare variation** | | This occurs where patients with the same condition receive different types of care. For example, among a group of patients with the same condition, some may have no active treatment, some may be treated in the community and others in hospital, and some may have surgery while others receive medication. Some variation in how health care is provided is desirable because of differences in patients’ needs, wants and preferences (see ‘unwarranted healthcare variation’). | |
| **Healthcare-associated infections** | | Infections that are acquired in healthcare facilities (nosocomial infections) or that occur as a result of healthcare interventions (iatrogenic infections). Healthcare-associated infections may manifest after people leave healthcare facilities.9 | |
| **Medication chart** | | A chart used by an authorised prescriber to record medication and treatment orders, as well as by nursing staff to record and monitor the administration of such medicines and treatment. | |
| **My Health Record** | | A secure online summary of a consumer’s health information, managed by the System Operator of the national e-health record system (the Secretary to the Australian Government Department of Health). Healthcare providers are able to share health records to a consumer’s My Health Record, in accordance with the consumer’s access controls. This may include information such as medical history and treatments, diagnoses, medications and allergies. Also known as a Personally Controlled Electronic Health Record. | |
| **National Safety and Quality Health Service (NSQHS) Standards** | | Standards developed by the Commission in consultation and collaboration with states and territories, technical experts, health service organisations and patients. The NSQHS Standards aim to protect the public from harm, and to improve the quality of health services. They provide a quality assurance mechanism that tests whether relevant systems are in place to ensure minimum safety and quality standards are met, and a quality improvement mechanism that allows health service organisations to realise aspirational or developmental goals. | |
| **Partnering with consumers** | | Treating consumers and/or carers with dignity and respect, communicating and sharing information between consumers and/or carers and health service organisations, encouraging and supporting consumers’ participation in decision-making, and fostering collaboration between consumers and/or carers and health service organisations in planning, designing, delivering and evaluating health care. Other terms are used internationally, such as patient-based, consumer-centred, person-centred, relationship-based, patient-centred, and patient- and family-centred care. | |
| **Patient** | | A person receiving health care. Synonyms for ‘patient’ include ‘consumer’ and ‘client’. | |
| **Patient safety** | | Reducing the risk of unnecessary harm associated with health care to an acceptable minimum. | |
| **Shared decision making** | | The integration of a patient’s values, goals and concerns with the best available evidence about the benefits, risks and uncertainties of treatment to achieve appropriate healthcare decisions.10 | |
| **Standard** | | Agreed attributes and processes designed to ensure that a product, service or method will perform consistently at a designated level. | |
| **Unwarranted healthcare variation** | | Variation not attributed to a patient’s needs, wants or preferences. It may reflect differences in clinicians’ practices, the organisation of health care or people’s access to services. It may also reflect poor-quality care that is not in accordance with evidence-based practice. | |

# Index of tables

|  |  |
| --- | --- |
| Table | Page |
| Table 1: Top core NSQHS Standards actions not met or met with merit | 18 |
| Table 2: *Second Australian Atlas of Healthcare Variation* key findings and recommendations | 39 |
| Table 3: Board meetings and attendance | 64 |
| Table 4: Remuneration paid to executives during 2016–17 | 70 |
| Table 5: Remuneration paid to highly paid staff during 2016–17 | 71 |
| Table 6: Employee profile as of 30 June 2017 | 76 |
| Table 7: Freedom of information summary 2016–17 | 108 |
| Table 8: Summary of the Commission’s compliance with ecologically sustainable development | 109 |
| Table 9: Related-entity transactions during 2016–17 | 110 |

# Index of figures

|  |  |
| --- | --- |
| Figure | Page |
| Figure 1: Health service organisation accreditation 2016–17 | 17 |
| Figure 2: Organisational structure | 74 |

# Compliance index

|  |
| --- |
| The Commission is bound by various legislative requirements to disclose certain information in its Annual Report. The operative provisions of the Public Governance, Performance and Accountability Act came into effect on 1 July 2014. The Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule 2016 prescribes the reporting requirements for the Commission. |

Mandatory reporting orders as required under legislation

| Requirement | Reference | Page listing compliant information |
| --- | --- | --- |
| Accountable authority | Public Governance, Performance and Accountability Rule, subsection 17BE(j) | 61–64 |
| Amendments to the Commission’s enabling legislation, and to any other legislation directly relevant to its operation | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(a) | 71 |
| Approval by the accountable authority | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, section 17BB | 1 |
| Assessment of the impact of the performance of each of the Commission’s functions | National Health Reform Act, subsection 53(a) | 16–57 |
| Assessment of the quality of healthcare services provided | National Health Reform Act, paragraph 53(b)(ii) | 47 |
| Board committees | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(j) | 67–68 |
| Ecologically sustainable development and environmental performance | *Environmental Protection and Biodiversity Conservation Act 1999*, section 516A | 71 |
| Enabling legislation, functions and objectives | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(a) | 6, 60 |
| Financial statements | Public Governance, Performance and Accountability Act, subsection 43(4) | 81–105 |
| Financial statements certification: Auditor-General’s Report | Public Governance, Performance and Accountability Act, subsection 43(4) | 82–83 |
| Financial statements certification: a statement signed by the accountable authority | Public Governance, Performance and Accountability Act, subsection 43(4) | 84 |
| Government policy orders | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(e) | 71 |
| Indemnities and insurance premiums for officers | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(t) | 65 |
| Judicial decisions and decisions by administrative tribunals | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(q) | 70 |
| Key activities and changes that have affected the Commission | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(p) | 70 |
| Location of major activities and facilities | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(l) | 76 |
| Ministerial directions | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(d) | 60 |
| Organisational structure | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(k) | 74–76 |
| Related-entity transactions | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsections 17BE(n) and (o) | 110 |
| Reporting of significant decisions or issues | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(f) | 70 |
| Reports about the Commission by the Auditor-General, a parliamentary committee, the Commonwealth Ombudsman or the Office of the Australian Information Commissioner | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(r) | 70 |
| Responsible Minister | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(c) | 6, 60 |
| Review of performance | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(g) | 49–57 |
| Statement on governance | Public Governance, Performance and Accountability Amendment (Corporate Commonwealth Entity Annual Reporting) Rule, subsection 17BE(m) | 69–70 |

Index

Page range references in **bold** type refer to major discussions of a topic.

A

abbreviations, **114–115**

Aboriginal and Torres Strait Islander Australians

hospitalisation rates, 38

staff, **78**

accountability, 6, 60

accreditation

Australian Health Service Safety and Quality Accreditation Scheme, **20**, 50

National General Practice Accreditation Scheme, 11, 16

review of accrediting agencies, 16–17

acronyms, **114–115**

advertising and market research, 71

anaemia, 26

annual performance statements, 49–57

entity purpose, **49**

performance, **50–51**

performance against Health Portfolio Budget Statements and Corporate plan 2016–17, **52–57**

antibiotic usage, 51

antimicrobial resistance, 11, **21–22**

Antimicrobial Use and Resistance in Australia (AURA) Surveillance System, 11, **21–22**, 51

AURA 2016: First Australian report on antimicrobial use and resistance in human health, 21

National Alert System for Critical Antimicrobial Resistances (CARAlert), 21

antipsychotic medication, 27–28

Atlas of Healthcare Variation, see Australian Atlas of Healthcare Variation; Second Australian Atlas of Healthcare Variation

Audit and Risk Committee, 67

audits

independent auditor’s report, **82–83**

internal, 69

AURA Surveillance System, *see* Antimicrobial Use and Resistance in Australia (AURA) Surveillance System

Australian and New Zealand Hip Fracture Registry, 42

Australian Atlas of Healthcare Variation, 8, 27, 37, 47, 51; see also Second Australian Atlas of Healthcare Variation

Australian Commission on Safety and Quality in Health Care

accountability, **6**, 60

Advice Centre, 16

corporate governance, 60, 69

key achievements 2016–17, 50–51

key performance indicators, 50, 52–57

mission, **6**

organisational structure, **74–75**

partnerships, 50

purpose and role, **6**, 9, 10, 49

strategic plan, 12–13

Australian Composite Model Hospital Standardised Mortality Ratio, 44

Australian Core Patient Experience Question Set, 45

Australian Digital Health Agency, 23

Australian health care safety and quality, 47–48

Australian Health Service Safety and Quality Accreditation (AHSSQA) Scheme, 50

revision of, **20**

Australian Public Service Commission, 76

B

bleeding, menstrual, 10, 34, 37, 39, 42, 44

blood transfusions, 26

Board

annual performance statements, **49–57**

committees, **67–68**

meetings and attendance, 64

membership 2016–17, **61–64**, 66

organisational structure, **74–75**

role, 61

Bowles, Martin, 62

C

Caring for Cognitive Impairment campaign, 27

CARAlert, 21

cardiac surgery heater-cooler devices and *Mycobacterium chimaera*, **22–23**

care appropriateness, **42**

CEO

report, **10–11**

role, 69

Chair, 61

annual performance statements, 49–57

letter of transmittal, 1

report, **8–9**

chronic obstructive pulmonary disease,   
39–40

clearing house portal for medication alerts and medical device safety notifications, 31

clinical care standards, 42, 44, 51

delirium, 10, 51

heavy menstrual bleeding and venous thromboembolism, 10, 34, 37, 39, 42, 44

hip fracture care, 10, 42, 51

osteoarthritis of the knee, 8, 10, 41, 42, 44, 51

review of, 42

see also Australian Atlas of Healthcare Variation; Second Australian Atlas of Healthcare Variation

Clinical care standards, 10, 42, 44, 57

clinical communication for safety, **28**

clinical governance framework, **29**, 51

National Model Clinical Governance Framework, 29

clinician education modules, 11

COAG, 6, 43

COAG Health Council 10–11

cognitive impairment, **27–28**

Caring for Cognitive Impairment campaign, 27

colonoscopy safety and quality model, **30–31**

Communicating for Safety Standard, **28**

compliance index, **120–122**

Comprehensive Care Standard, **29–30**

consumer resources, 11

Core Hospital-Based Outcome Indicators, 44

corporate governance, 60–71

advertising and market research, **71**

Board, **61–66**

committees, **67–68**

environmental performance and sustainable development, **71**

external scrutiny, **70**

government policy orders, 71

internal governance, **69**

legislation requirements and compliance, **60**

ministerial directions, **60**

National Health Reform Act amendments, 71

significant events, **71**

strategic planning, **60**

Corporate Plan 2016–17, 52

performance against, **52–57**

Council of Australian Governments, *see* COAG

D

Data Governance Framework, 44

Data Plan 2016–2019, 44

delirium, 10, 51, 57

Della, Professor Phillip, 63

device safety, **31–32**

diabetes complications, 40

dementia, see cognitive impairment

digital patient safety, **23–24**

Barcoding and Other Scanning Technologies to Improve Medication Safety in Hospitals report, 24

Implementation of Electronic Medication Management Systems in Hospitals: A literature scan, 23

Literature Review and Environmental Scan on Approaches to the Review and Investigation of Health IT-Related Patient Safety Incidents, 23

National Guidelines for On-Screen Presentation of Discharge Summaries report, 24

disability strategy, **78**

E

ecologically sustainable development, **71, 109**

*Economic Evaluation of Clinical Quality Registries*, 46

employees, *see* staff

end-of-life care, **35**

endometrial ablation, 37, 39

environmental performance, 71

external scrutiny, **70**

F

Filby, Dr David, 62

financial statements, 81–105

Cash Flow Statement, **88**

financial performance, **92–95**

financial position, **96–99**

independent auditor’s report, **82–83**

managing uncertainties, **103–104**

overview, **90–91**

people and relationships, **100–102**

Statement by the Directors, Chief Executive and Chief Financial Officer, **84**

Statement of Changes in Equity, **87**

Statement of Comprehensive Income, **85**

Statement of Financial Position, **86**

Framework for Australian Clinical Quality Registries, 46

fraud control, 69

freedom of information, 70, **108**

G

Gee, Christine, 63

glossary, **116–118**

government policy orders, 71

H

hand hygiene, 22, 44

Harris, Wendy, 63

healthcare

healthcare-related harm, 45–46

quality 44–46

variation, **37**; see also Australian Atlas of Healthcare Variation; Second Australian Atlas of Healthcare Variation

Health Portfolio Budget Statements   
2016–17, 52–57

heavy menstrual bleeding, 10, 34, 37, 39, 42, 44

hip fracture care, 10, 42, 51, 57

Hip Fracture Care – The case for improvement, 42

hospitals

avoidable readmissions, 43, 48

hospital-acquired complications, 43, 45–46, 48

hospitalisation rates, 37–38, 43

pricing and funding, 11, 43, 48

Hunt, Greg (Minister for Health), 6

hysterectomy, 37, 39

I

Income Statement, **85**

Independent Hospital Pricing Authority (IHPA), 43, 48

Indigenous recruitment and employment, **78**

infection control, 21–23

injection of erroneous substances, 31–32

insulin charts, 25

Inter-Jurisdictional Committee, 68

internal governance, **69**

iron deficiency, 26

K

knees

osteoarthritis, 8, 41, 44, 51

replacement, 41

L

labelling, 25

Larkin, Dr Shaun, 63

learning and development, **77**

letter of transmittal, 1

M

Marshall, Professor Villis (Chair), 1, 8–9,   
49, 61

maternal morbidity, 44

medical devices

safety notifications, 31

small-bore connectors for liquids and gases in healthcare applications, 31–32

medication safety, **25–26**

medication alerts, 31

Medication Safety in Mental Health report, 25

Pharmaceutical Benefits Scheme (PBS) Hospital Medication Chart, 25

Recommendations for Terminology, Abbreviations and Symbols Used in Medicines Documentation, 25

menstrual bleeding, 10, 34, 37, 39, 42, 44

mental health, **27**

Fifth National Mental Health and Suicide Prevention Plan, 27

and medication safety, 25

National Consensus Statement: Essential elements for recognising and responding to deterioration in a person’s mental state, 27

Minister for Health, 6, 60, 61

*Mycobacterium chimaera* and cardiac surgery heater-cooler devices, **22–23**

My Health Record system, 23–24

Clinical Incident Management Unit, 23

N

National Alert System for Critical Antimicrobial Resistances (CARAlert), 21

National Bowel Cancer Screening Program, 30

national clinical quality registries, 46

National General Practice Accreditation Scheme, 11, 16

National Guidelines for On-Screen Display of Consumer Medicines Information, 36

National Guidelines for On-Screen Display of Clinical Medicines Information, 36

National Health and Hospitals Network Act 2011, 6

National Health Reform Act 2011, 6, 49, 60

amendments 71

National Health Reform Agreement, 43

National Model Clinical Governance Framework, 29

National Patient Blood Management Collaborative, **26**

National Safety and Quality Health Service (NSQHS) Standards

Advice Centre, 10

aims, 16

Communicating for Safety, 28

Comprehensive Care Standard, **29–30**

implementation, **16–18**, 50

introduction of, 8, 10

model for colonoscopy, **30–31**

person-centred healthcare, 33

and primary care, 50

quality management, 47

review of first edition, 19

second edition, 8, 10, **19**, **20**, 29, 47, 50

national sentinel events list, 45–46

O

on-screen presentation of medicines information, **36**

organisational structure, **74–75**

osteoarthritis of the knee, 8, 41, 44, 51, 57

P

partnering with patients, consumers and communities, 12–13, **33–36**

end-of-life care, **35**

national guidelines for on-screen presentation of medicines information, **36**

performance against *Health Portfolio Budget Statements and Corporate Plan* 2016–17, 54–55

person-centred healthcare systems, **33**

shared decision making and health information, **34–35**

supporting consumers to be partners in their own care, **34**

patient safety, 12–13, 16–32

AURA Surveillance System, 11, **21–22**, 48, 51

clinical communication, **28**

clinical governance framework, **29**

cognitive impairment, **27–28**

communicating for safety, **28**

Comprehensive Care Standard, **29–30**

device safety, **31–32**

digital patient safety, **23–24**

implementation of NSQHS Standards, **16–18**

medication safety, **25–26**

mental health, **27**

*Mycobacterium chimaera* and cardiac surgery heater-cooler devices, **22–23**

National Patient Blood Management Collaborative, **26**

national safety and quality model for colonoscopy, **30–31**

NSQHS Standards second edition, development of, **19**

performance against *Health Portfolio Budget Statements and Corporate Plan 2016–17*, 52–54

in primary health care, **24–25**

and quality in Australian health care, **47–48**

response to *Mycobacterium chimaera* and cardiac surgery heater-cooler devices, **22–23**

revision of AHSSQA Scheme, **20**

patients, consumers and communities, *see* partnering with patients, consumers and communities

PBS Hospital Medication Chart, 25

performance statements, *see* annual performance statements

person-centred healthcare systems, **33**

Portfolio Budget Statements *see* Health Portfolio Budget Statements

Picone, Professor Debora (CEO), 10–11

post-partum haemorrhage indicators, 44

Primary Care Committee, 68

primary health care

patient safety, **24–25**

Primary Care Safety and Quality Framework Committee, 24

Prioritised List of Clinical Domains for Clinical Quality Registry Development, 46

Private Hospital Sector Committee, 68

Public Governance, Performance and Accountability Act 2013, 49, 52, 60, 65

Public Governance, Performance and Accountability Rule 2014, 52, 60

Q

quality, cost and value, 12–13, 37–43

identifying healthcare variation, **37**

improving appropriateness of care, **42**

performance against Health Portfolio Budget Statements and Corporate Plan 2016–17, 55–56

pricing for safety and quality, **43**

reports on clinical quality registries, 46

see also Second Australian Atlas of Healthcare Variation

Question Builder (web-based patient tool), 11, 35, 51

R

related-entity transactions, **110**

remuneration

executives, 70

highly paid staff, 71

reports

AURA 2016: First Australian report on antimicrobial use and resistance in human health, 21

Barcoding and Other Scanning Technologies to Improve Medication Safety in Hospitals report, 24

Medication Safety in Mental Health report, 25

National Guidelines for On-Screen Presentation of Discharge Summaries   
report*,* 24

risk management, 69

Royal Australian College of General Practitioners (RACGP), 11

Standards for general practices, 16

Royle, Cheryle, 64

S

safety, *see* patient safety

safety and quality in Australian health care,   
**47–48**

Safety, Rehabilitation and Compensation Act 1988, **77**

Second Australian Atlas of Healthcare Variation, 8, 10, 37–38, 39–41, 47, 51

shared decision making and health information, **34**

significant developments and events, 71

staff, 73

disability strategy, **78**

Indigenous employment, **78**

learning and development, **77**

profile, **76**

remuneration, 70–71

workplace health and safety, **77**

standards

Communicating for Safety Standard, 28

Comprehensive Care Standard, **29–30**

RACGP *Standards for general practices*, 16

*see also* National Safety and Quality Health Service (NSQHS) Standards

strategic plan, **12–13**, 60

*see also* partnering with patients, consumers and communities; patient safety; quality, cost and value; supporting health professionals to provide safe, high-quality care

supporting health professionals to provide safe, high-quality care, 12–13, 44–46

indicators and dataset specifications, **44**

minimising healthcare-related harm, **45**

national clinical quality registries, **46**

patient-reported experience measures, **45**

performance against Health Portfolio Budget Statements and Corporate Plan 2016–17, 56–57

T

Toolkit for Developing Safety and Quality Indicators, 44

Top Tips for Safe Health Care, 11, 34, 51

U

uterine bleeding, 10, 37

V

variation in healthcare, **37**; *see also* Australian Atlas of Healthcare Variation; Second Australian Atlas of Healthcare Variation

venous thromboembolism, 42, 44

Vital Signs 2016–17, p48

W

Walsh, Professor John, 62

Williams, Dr Helena, 64

*Work Health and Safety Act 2011*, 77

workplace health and safety, **77**

# References

1. Primary Health Care Advisory Group. Better outcomes for people with chronic and complex health conditions. Canberra: Department of Health; 2015.

2. Starfield B, Macinko J. Contribution of primary care to health systems and health. Milbank Q. 2005;83:457–502.

3. Australian Commission on Safety and Quality in Health Care. AURA 2016: first Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2016.

4. National Patient Safety Agency. Seven steps to patient safety. London: NPSA; 2004.

5. Australian Commission on Safety and Quality in Health Care. A better way to care: safe and high-quality care for patients with cognitive impairment (dementia and delirium) in hospital. Sydney: ACSQHC; 2014.

6. Consumers Health Forum of Australia. About consumer representation [Internet]. Australia: CHF; [cited 2017 1 June]; Available from: **www.chf.org.au/representation**.

7. National Institute for Health and Clinical Excellence. Delirium: diagnosis, prevention and management. London: NICE; 2010.

8. General Medical Council. Treatment and care towards the end of life: good practice in decision making [Internet]. United Kingdom: GMC; [cited 2017 1 June]; Available from:   
**www.gmc-uk.org/guidance/ethical\_guidance/end\_of\_life\_care.asp**.

9. Cruickshank M, Ferguson J editors. Reducing harm to patients from health care associated infection: the role of surveillance. Sydney: ACSQHC; 2008.

10. Hoffmann TC, Légaré F, Simmons MB, McNamara K, McCaffery K, Trevena LJ, et al. Shared decision making: what do clinicians need to know and why should they bother? Med J Aust. 2014;201:35–9.